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ABSTRACT
Makley, Meghan Katherine. M.S., Department of Biochemistry and Molecular Biology, 
Wright State University, 2009.
NMR Analyses Show TCDD Elicits Differences in Hepatic Metabolism in Female 
C57BL/6 Mice and Sprague-Dawley Rats.
TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) elicits tissue-, sex-, and species-
specific effects.  This study compares the hepatic response to an oral dose of TCDD in 
immature ovariectomized (i.o.) C57BL/6 mice (30 µg/kg) and i.o. Sprague-Dawley rats 
(10 µg/kg), at 72, 120, and 168 h post-dose.  Hepatic lipid extracts were analyzed by 13C 
and 31P NMR, and aqueous extracts by 1H and 31P NMR.
Consistent with increased lipid content in mice (p≤0.05), TCDD induced 
increases in hepatic triacylglycerides (TAG), cholesterol, and fatty acids.  Principal 
component analysis of 13C spectra show treatment groups separate in mice, but not rats. 
Mice showed decreases in the lactate/pyruvate ratio and dihydroxyacetone phosphate, 
consistent with decreased cytosolic NADH/NAD+ ratio and upregulated TAG synthesis. 
TCDD-treated rats exhibited decreased levels of sphingomyelin, and three-fold increase 
in phosphocholine, suggesting TCDD activates sphingomyelinase.  Both species showed 
similar decreases in cardiolipin, indicating oxidative stress.  These observations are 
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I.  INTRODUCTION
The aryl hydrocarbon receptor (AhR) is a cytosolic ligand-activated member of 
the basic-helix-loop-helix Per (Period)-ARNT (aryl hydrocarbon nuclear translocator)-
SIM (single-minded) (bHLH-PAS) domain superfamily of proteins.  This family of 
proteins mediates the toxic effects of halogenated aromatic hydrocarbons.  Halogenated 
aromatic hydrocarbons are a group of widespread, persistent, and toxic environmental 
contaminants that include the polychlorinated dibenzo-p-dioxins, dibenzo-furans, and 
biphenols (Schecter et al., 2006).  The structure of 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD, dioxin) consists of two benzene rings connected by two oxygen atoms and 
contains four chlorines.  TCDD has a long half-life.  In humans, it is seven to eleven 
years (Pirkle et al., 1989), and in rodents, it is two to four weeks (Rose et al., 1976).
These compounds are formed during the production of halogen-containing 
aromatics, such as herbicides (Agent Orange) during the Vietnam War, and during the 
combustion of dust or bleaching of pulp at paper mills.  Cases of TCDD exposure occur 
via industrial accidents, occupational exposure, or environmental pollution, such as 
volcanic emissions.  Another well-known instance was in 1976, when a trichlorophenol 
manufacturing plant exploded in Seveso, Italy.
Type-2 diabetes has been associated with TCDD exposure among Vietnam 
veterans exposed to Agent Orange (Fujiyoshi et al., 2006), those exposed to TCDD in 
Seveso, Italy (Bertazzi et al., 1998), and other industrial workers (Vena et al., 1998).  
1
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People with high levels of TCDD demonstrate insulin resistance (Cranmer et al., 2000).  
TCDD induces a broad spectrum of additional effects such as the induction of 
metabolizing enzymes (cytochrome-P450), cancer, immunotoxicity, hepatotoxicity, 
endocrine disturbances, and wasting syndrome.  The wasting syndrome is a failure to 
gain weight at normal rates, or in more severe cases, weight loss.  Non-alcoholic fatty 
liver disease, the metabolic syndrome, and obesity are also linked to TCDD.  
Interestingly, TCDD causes different phenotypic responses in different species 
and even in different strains of some species.  There is a wide range of lethal doses 
(LD50s) in rodents.  Guinea pigs are very sensitive to TCDD (LD50 = 1 µg/kg) and 
hamsters are among the most resistant (LD50 = 1000 µg/kg).  The species used in this 
study, C57BL/6 mice and Sprague Dawley rats, have LD50s of 120 µg/kg and 30 µg/kg, 
respectively (Bickel 1982; Vos et al., 1974).  
Classic rodent responses that are observed include effects on liver and body 
weight gain (Poland and Knutson, 1982).  One study, using these same strains, reported 
that liver weights of both TCDD-treated rats and mice significantly increased compared 
to vehicle controls after 72 and 168 hours (p<0.05).  In rats, body weight gain 
significantly decreased compared to controls at 72 and 168 hours.  Mice showed no 
significant alterations in body weight or body weight gain (Boverhof et al., 2006).  
Histochemical findings in both species were reported in this same study 
(Boverhof et al., 2006).  TCDD-treated rats exhibit minimal to moderate hepatocellular 
hypertrophy in the centriacinar regions of the liver.  Such hypertrophy included enlarged 
hepatocytes, and a more granular, eosinophilic and less vacuolated cytoplasm compared 
to controls.  In TCDD-treated mice, vacuolization was first observed in the periportal and 
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midzonal regions, and then the centriacinar regions.  Also, vacuolization was progressive 
from 72 to 168 hours, at which point cell apoptosis occurred.  Oil Red O staining 
confirmed that this vacuolization was due to lipid accumulation, and this was observed in 
mouse but not rat liver.
The mechanisms of toxicity in rats and mice are not understood, but likely deal 
with the AhR signaling pathway.  Most of TCDD’s effects require activation of the AhR, 
which results in transcriptional induction or repression of genes (Puga et al., 2000), 
including those of the Ah gene battery (Hankinson et al., 1991; Hankinson 1995; Kafafi 
et al., 1993; Nebert 1989; Nebert et al., 1993, 2000).  The AhR-binding affinity for 
TCDD is similar between rats and mice, so it cannot explain the difference in sensitivity 
(Denison et al., 1986; Poland et al., 1976).  The rat and mouse AhR are comparable but 
not identical molecular species and differ in molecular weights (Denison et al., 1986). 
There is high homology in the amino acid sequences except in a 42-amino acid truncation 
at the C-terminal end of mouse AhR when compared to rat.  Therefore, differences in the 
AhR transactivation domain may explain differential gene expression responses and 
altered sensitivity of these strains.  However, this was reported for Han/Wistar and Long-
Evans rats (Okey et al., 2005), strains not used in this study.  Differences in genomic 
sequences at promoter and enhancer regions are an alternative explanation for the species 
differences (Sun et al., 2004).
The mechanisms of toxicity are also believed to be related to estrogen receptors 
(ER), endocrine disruptors, and estradiol, so immature ovariectomized (i.o.) female 
rodents were used.  Other groups found that the mechanisms of toxicity are estrogen-
dependent in rat liver (Lucier et al., 1991; Sewall et al., 1993).  In rats, females appear 
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more sensitive to liver carcinogenicity of TCDD.  Ovariectomy inhibited the promotion 
of TCDD-induced preneoplastic foci and liver tumors; hence, ovarian hormones are 
believed to play a role (Lucier et al., 1991).  Petroff and coworkers found that estrogen 
amplified TCDD-induced changes in body weight and hepatic cytochrome-P450 enzyme 
induction (Petroff et al., 2001).  Kociba and coworkers found that dietary administration 
of TCDD for two years to Sprague Dawley rats induces liver tumor formation in females, 
but not males, and this response seems to be linked to hormone expression (Kociba et al., 
1978).
The AhR also appears to be linked to endocrine disruptors as well as estrogen. 
The AhR and ARNT are present in mammary tissues, and inactivation of these proteins 
results in impaired mammary development and lactation (Abbott et al., 1999; Birnbaum 
and Fenton 2003; Hushka et al., 1998; Le Provost et al., 2002; Warner et al., 2002). 
Vorderstrasse and coworkers reported that AhR activation during pregnancy disrupts 
mammary gland differentiation (Vorderstrasse et al., 2004).  Mammary tissue may be 
susceptible to injury by endocrine disruptors.  Also, TCDD and AhR modulators can 
activate inhibitory AhR-ER-α crosstalk in the uterus and breast and endometrial cancer 
cells (Safe 2001).
This study uses NMR-based quantitative metabolomics to compare hepatic effects 
of TCDD in rats and mice.  Three genomic studies reveal genes or mRNA expression that 
are 1) regulated by the AhR or 2) altered after TCDD administration in vivo. 
Zacharewski and coworkers investigated TCDD-induced temporal changes in hepatic 
gene expression and serum clinical chemistry, and proposed a mechanism of 
hepatotoxicity in mice (Boverhof et al., 2005).  They identified genes uniquely up- or 
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downregulated in mice and rats, as well as conserved responses (Boverhof et al., 2006). 
Fletcher and coworkers studied mRNA expression in liver; however, they used male 
Sprague-Dawley rats after a single administration of 40 µg TCDD/kg body weight 
(Fletcher et al., 2005).  One must be careful when making comparisons to i.o. female rats. 
The metabolic pathways differently affected by TCDD in mice and rats were identified 
using the metabolic data presented here, and then compared with these mRNA and gene 
expression findings.  
II.  MATERIALS AND METHODS
A.  MATERIALS
Chemicals:  Methanol and chloroform came from Fisher-Scientific; deuterium oxide 
(D2O), deuterchloroform (CDCl3), trimethylsilyl-3-propionic acid sodium salt (TSP), 
ethylenediaminetetraacetic acid (EDTA), and methylenediphosphonic acid (MDPA) from 
Sigma-Aldrich (St. Louis, MO); Chelex 100 from BIORAD, and liquid nitrogen from 
Weiler Welding (Dayton, OH).
Animals:  Female Sprague Dawley rats and C57BL/6 mice came from Charles River 
Laboratories (Raleigh, NC).
NMR Spectroscopy Analysis:  Varian NMR (VNMR) version 6.1 computer system 
came from Varian Inc. (Houston, TX); JMP statistical software from SAS (Cary, NC); 
and Chenomx NMR suite version 5.0 profiler and processor (Edmonton, Alberta).
B.  METHODS
Animal Protocol
Female Sprague Dawley rats and C57BL/6 mice, ovariectomized by the vendor 
on post-natal day (PND) 20 and all having body weights within 10% of the average body 
weight, were obtained from Charles River Laboratories (Raleigh, NC) on PND 25.  This 
model has been previously used to investigate the effects of TCDD (Boverhof et al., 
2005, 2006) on clinical chemistry, hepatic gene expression, and histopathology.  It was 
used in the present study to obtain metabolomic data elucidate the mechanisms associated
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with TCDD-elicited hepatotoxicity.  Animals were housed in polycarbonate cages 
containing cellulose fiber chips (Aspen Chip Laboratory Bedding, Northeastern Products, 
Warrensberg, NY) in a 23 °C high-efficiency particulate air-filtered environment with 30-
40% humidity and a 12-hour light/dark cycle (0700-1900 hours).  Animals were allowed 
free access to deionized water and Harlan Teklad 22/5 Rodent Diet 8640 (Madison, WI), 
and acclimatized for four days prior to dosing.  On the fourth day, animals were weighed, 
and a stock solution of TCDD (provided by S. Safe, Texas A&M University, College 
Station, TX) was diluted in sesame oil (Sigma, St. Louis, MO) to achieve the desired 
dose based on the average weight.  Doses were chosen to elicit moderate hepatotoxicity 
without overt toxicity and were based upon cytochrome-P450 enzyme (CYP1A1) 
induction.  C57BL/6 mice were treated with either 0.1 mL of sesame oil (vehicle control, 
n=5) or 30 µg/kg TCDD in sesame oil (treated, n=5) by oral gavage.  Sprague Dawley 
rats were treated with 0.1 mL of sesame oil or 10 µg/kg TCDD (n=5 per group), also by 
oral gavage.  
At 72, 120, or 168 hours post-dose, animals were sacrificed by cervical 
dislocation, and livers were removed, weighed, and frozen in liquid nitrogen.  Animal 
work was done at Michigan State University, with the approval of its All-University 
Committee on Animal Use and Care.  Livers (ca. 0.5 g) were shipped overnight on dry 
ice to Wright State University (Cox Institute) in Dayton, Ohio for extractions and NMR 
spectroscopy analyses. 
Dual-Phase Extraction Procedure
A three-day dual-phase extraction procedure yielded aqueous and lipid extracts 
from ca. 0.5 g of liver.  On day one, individual livers were crudely pulverized under 
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liquid nitrogen with mortar and pestle and then weighed.  Ground livers were 
homogenized in 0.7 mL/100 mg liver in a 1:1:1 volume of methanol, chloroform, and 
water using a glass tissue grinder with a Teflon pestle.  The homogenate was allowed to 
sit in an ice bath for fifteen minutes.  The mixture was transferred to a 50 mL glass 
centrifuge tube and spun at 2000 x g for 25 minutes at 4 °C.  The sample was transferred 
through filter paper (pre-washed with 0.5 mL each of water, chloroform, and methanol) 
into a separatory funnel (set in a refrigerator at 4 °C).  The pellet was washed three times 
with 0.5 mL each of water, chloroform, and methanol.  After each wash, the pellet was 
homogenized, left in an ice bath for five minutes, and centrifuged for five minutes.  The 
supernatant was then transferred to the separatory funnel.  The separatory funnel was left 
at 4 °C for 17-24 hours to allow complete separation of the two phases.  
On day two, the upper phase (aqueous constituents) was drawn off using a 
disposable pipette into a clear vial.  The lower, organic phase (lipids) was removed to an 
amber vial and evaporated to dryness using a gentle stream of nitrogen gas.  The funnel 
was washed three times with 0.5 mL each of water, chloroform, and methanol.  The 
aqueous phase was partially evaporated under nitrogen gas to remove most of the 
methanol, and then lyophilized to dryness overnight.  The lipid extract was placed under 
mild vacuum overnight to ensure complete dryness.  On day three, each vial was weighed 
to obtain total content.  The lipids were reconstituted in CDCl3, and then both vials were 
stored at -20 °C. 
NMR Spectroscopy of Liver Extracts
Sample preparation for NMR spectroscopy acquisition differed for lipid and 
aqueous extracts, and is described in their respective sections below.  All samples, after 
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reconstitution, were placed in a 5-mm NMR tube.  All NMR spectra were acquired using 
a Varian INOVA spectrometer at 14.1 T.  13C, 31P, 1H NMR spectroscopy were performed 
at 150, 243, and at 600 MHz, respectively.  All data were acquired in field-lock mode 
using the deuterium signal from CDCl3. 
1. NMR Spectroscopy of Lipid Extracts
Lipid samples were reconstituted in 600 µL D2O with 1.04 mM TSP in D2O 
added as a chemical shift reference at 0.0 ppm.  500 µL of this reconstituted sample were 
added to the NMR tube.  Quantitative 13C and 31P NMR spectroscopy were performed on 
the hepatic lipid extracts.  High resolution proton-decoupled 31P and 13C NMR spectra 
were acquired in field-lock mode using a 5-mm probe operating at 242.8 and 150.8 MHz, 
respectively.  The sample temperature was regulated at 20 °C in order to obtain optimal 
spectral resolution (Adinehzadeh et al., 1998).  13C and 31P lipid samples were acquired 
with the Nuclear Overhauser Effect (NOE) using a gated 1H-decoupling sequence.  Data 
acquisition parameters for 31P included a 90 ° pulse, 645 Hz spectral bandwidth, 1.6 
second acquisition time, 10.6 second interpulse delay (full T1 relaxation) and ca. 2.25 
hours of signal averaging.  13C samples were acquired using a 70 ° pulse, 35 kHz spectral 
bandwidth, 1.3 second acquisition time, 1.9 second interpulse delay and ca. 15 hours of 
signaling averaging.
Preparation of Cs2EDTA Salt 
For the 31P NMR, a 90 mM Cs2EDTA solution was made to help improve the 
signal to noise resolution.  A 1 M solution of EDTA free acid was made in a total volume 
of 3 mL, as well as a 0.6 M CsOH solution in a total volume of 15 mL.  The EDTA 
solution was titrated with the CsOH solution to pH 6.0, using ca. 10 mL of CsOH.  The 
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solution was frozen and lyophilized to dryness.  During the preparation of this 90 mM 
Cs2EDTA solution, crystals were dissolved in 1 mL distilled deionized water, to which 4 
mL of methanol were added (Meneses et al., 1988).  To the NMR tube, 200 µL of this 
Cs2EDTA solution were added.  The solution was agitated, and the tube was allowed 45 
minutes for separation.  In some cases, an additional 25 µL of Cs2EDTA needed to be 
added to improve the signal to noise resolution of certain phospholipids.  The 31P NMR 
spectroscopy was run after the 13C. 
2. NMR Spectroscopy of Aqueous Extracts
Dried aqueous extracts were treated with Chelex 100 and 2 mL water to remove 
divalent cations, and then lyophilized to dryness again.  Samples were reconstituted in 
750 µL of 1.04 mM TSP in D2O, 650 of this volume transferred to an NMR tube for the 
1H NMR spectroscopy.   Aqueous samples were run at 25 °C.  After the 1H NMR was 
finished, 50 µL of a 2:1 mix of Na2EDTA (215 mM) to MDPA (84.7 mM) solution was 
added for 31P NMR spectroscopy.  The 1H decoupler was used only when running the 31P 
NMR spectroscopy.  
Spectral Data Analysis
All spectral processing was done on a Sun Microsystems computer using VNMR 
version 6.1 software (Varian Inc. Houston, TX) that utilized exponential multiplication 
yielding 0.3, 0.5, and 1 Hz line-broadening, for 1H, 13C, and 31P, respectively.  The first 
step was to perform weighted Fourier transformation of the free induction decay, or FID. 
Then, the spectrum was phased and baseline corrected.  For the lipid extracts, the 
reference was set to the center peak of CDCl3 at 77.79 ppm for 13C NMR spectra and to 
phosphatidylcholine (PtdC) at -0.84 ppm for 31P NMR spectra; and for the aqueous 
11
extracts, to TSP at 0.0 ppm for 1H NMR spectra and to glycerophosphocholine (GPC) at 
3.082 ppm for 31P NMR spectra.  GPC was chosen relative to phosphocreatine at 0.0 
ppm; however, the liver does not contain phosphocreatine.  The chemical shift of GPC is 
not pH-sensitive. 
31P NMR spectra of lipids were fit by Lorentizian line-shape analysis (due to 
simplicity).  All peaks of interest were thresholded, deconvoluted, and then integrated. 
Metabolites were quantified based on the PtdC integral.  
Several samples had to be spiked in order to verify the chemical shift assignment 
of several metabolites.  This was necessary because of slight differences in pH from 
sample to sample, since many phosphorus signals are pH dependent.  Our liver extracts 
are believed to be at pH 7-8.  Spiking was done by adding a small amount of the 
metabolite to an old liver sample, and running NMR spectroscopy.  The spectrum with 
the spiked sample was compared to the original spectrum of that sample (used for 
processing, quantification, etc.) to determine which peak that metabolite represented.  A 
general flowchart of the entire experimental protocol can be seen in Appendix B. 
Data Processing for PCA
13C NMR spectra were divided into 1024 bins and 1H NMR spectra into 280 bins. 
Principal Component Analysis (PCA) was performed, to characterize changes in the lipid 
profiles in each species.  PCA reduces multidimensional data sets to lower dimensions for 
analysis, and looks for patterns (pattern recognition analysis).  It is an unsupervised 
method, in that it does not know which data set is treated or control, etc (Jahns et al., 
2008).  After PCA was performed, the signals of metabolites of interest were quantified. 
Peak integrals were quantified relative to the known concentration of CDCl3 solvent in 
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the NMR tubes, after correction for T1 saturation.  Data were normalized to the total lipid 
weight per gram of liver. 
All 1H spectra were analyzed using a website developed by a bioinformatics 
research group at Wright State (http://birg.cs.wright.edu/cox/user_login/login).  The xy 
files are loaded to the website, and a new analysis is created, to which collections of 
spectra can be added.  The operations are performed on these spectral groups.  Spectra 
were cropped to start at 11.6 ppm.  Then, the threshold range was set to {11.6, 10.0; 
-0.18, -2}.  The number of standard deviations was set to three, and the number of spikes 
to four.  Then, the spectrum was cropped to 10 to 0.18 ppm to mark the water region for 
deletion.  The region at 5.09 to 4.58 was zeroed.  This region also includes the glucose 
doublet, as this varied across animals due to interference from the water signal.  After the 
processing step, PCA was then run, and then the t-test, bin-by-bin, to evaluate control vs. 
treated differences at each time-point.  Then, the Orthogonal Partial Least Squares 
Discriminant Analysis (OPLS-DA) test was performed. 
Quantification
In order to do the quantification on a µmol/g liver basis, the final volume in the 
NMR tube needs to be obtained.  This was done by adding the volume of sample 
transferred to the NMR tube and the volume of 1:2 MDPA:EDTA solution added to the 
NMR tube. 
The next step was to determine the concentration of CDCl3 in the NMR tube. 
This could be obtained, knowing the concentration of the stock that was made.
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In the case of the 31P NMR spectra of aqueous extracts, the intensity of MDPA 
started out at 100, but needed to be corrected for the number of equivalent phosphorus, of 
which MDPA has two.  Here, the corrected intensity of MDPA is 50. 
For the quantification of lipids, the volume of the organic phase was corrected, 
taking into consideration the temperature of the lab and density.  Adding some amount of 
distilled water to an NMR tube, the tube was weighed and the height of the water 
measured.  The volume was calculated from 1) its density and weight, and 2) the volume 
of the cylinder or tube.  The ratio of the true volume to calculated volume was obtained. 
The procedure was repeated three times, and the average and standard error obtained.  
The change in volume factor was found to be 0.355.  The final volume in the 
NMR tube of the CDCl3 phase was found to be 0.571, based on the volume of the sample 
transferred to the tube added to 0.355 multiplied by the volume of Cs2EDTA. 
After inputting the intensities for each animal, the intensity was divided by the 
number of equivalent carbons represented in the spectrum.  The intensity ratio measured, 
would be derived by taking the intensity and dividing that by that of MDPA, or 50.  Then 
the intensity ratio (corrected for T1 saturation and the NOE), is determined.  This 
correction involved acquiring data under fully relaxed (FR) acquisition conditions for a 
representative sample (5 T1’s without NOE; interpulse delay of 250 s).  The ratio of the 
intensity of a peak of interest to the intensity of CDCl3 (quantification standard) was then 
calculated for FR and partially saturated (PS) spectra.  Saturation factors (SFs) were then 
determined by calculating the ratio of FR to PS intensities for each peak of interest.  This 
ratio was normalized to the intensity of the metabolite peak and to the solvent CDCl3. 
Now the concentration of the metabolite in the NMR tube can be obtained, which 
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would be the concentration of MDPA in the tube, multiplied by the intensity ratio that has 
been corrected for T1 saturation.  This number is then multiplied by the final volume in 
the tube divided by the volume of sample transferred to the NMR tube to obtain the 
concentration of that metabolite in the reconstituted sample, also in mM.  This number is 
multiplied by the volume of D2O used for sample reconstitution to get the quantity of 
your metabolite in µmol, and then this µmol number is divided by the number of grams 
of liver in the sample to get µmol/g liver. 
The concentration of PtdC from the 13C spectrum was obtained based on the 
concentration of CDCl3, and was used to quantify all the phospholipids, on a µmol/g of 
liver basis.  See Appendix C for sample calculations.
1H NMR Spectroscopy of Aqueous Extracts
Chenomx NMR suite (version 5.0) profiler and processor were used to determine 
the concentration of lactate (in mM) in the 1H aqueous NMR sample.  Line-broadening of 
0.3, phasing, and linear baseline correction were performed.  The water region was also 
deleted.
Statistical Analysis 
Statistical analyses involving more than two groups utilized an analysis of 
variance (ANOVA).  The three-factor ANOVA or multifactor test was used to assess 
significant differences among species (mouse vs. rat), treatment (control vs. treated), and 
time (72, 120, and 168 hours).  If the p-value was less than or equal to 0.05, the data were 
considered statistically significant.  However, if the three-factor ANOVA was not 
significant (p>0.05), the two-factor ANOVA was performed, evaluating the effects on 
treatment and time, time and species, or treatment and species.  If the two-factor ANOVA 
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proved not significant, the one-factor ANOVA was then used, to assess significant 
differences among treatment groups or across time.  For each significant effect of 
treatment, the Fisher least squares means (LSM) and Tukey honestly significant 
differences (HSD) tests were used for comparison of multiple group means.  The 
Student’s t-test was used to determine the effects of TCDD across treatment at each time 
post-dose, or across time with each treatment.  Error estimates are given as standard error 
of the mean (SE), and n-values are given in the legends to figures.  See Appendix D for a 
flowchart of the ANOVA tests.
III.  RESULTS
NMR spectroscopy of the lipid and aqueous phases of the liver extracts was used 
to identify significant quantitative changes in metabolites between control and treated 
groups, mice and rats, and over time post-dose with TCDD.  Also examined were the 
hepatic lipid and aqueous content per gram of liver.  Results from the hepatic lipid and 
aqueous extracts are discussed below in their respective sections.
A.  LIPID EXTRACTS
1.  Effects of TCDD on Mean Total Hepatic Lipid Content
Figure 1 shows the mean liver lipid content (mg lipid/g liver) in TCDD-treated 
and vehicle control animals (mice and rats) at 72, 120, and 168 hours post-dose.  A three-
factor ANOVA was conducted using species (mouse and rat), treatment groups (treated 
and control), and time (72, 120, and 168 hours) as factors.  The three-factor ANOVA 
shows that the data in the whole model of mean lipid content is significant (p=0.0014). 
This whole model analysis indicates that significant differences occur between species 
and treatment groups (p=0.0128), but not across time.  Treated vs. control mice show the 
largest differences, with mean liver lipid content 34-55% greater in treated mice relative 
to controls across time.  Treated vs. control rats do not show significant differences. 
The one-factor ANOVA was also conducted, within each species, to examine 
significant differences across time (72, 120, and 168 hours) or between treatment groups 
(treated vs. control).  In mice, mean lipid content in treated animals is significantly higher 
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relative to controls at 72 (p=0.0037) and 168 (p=0.0476) but not 120 hours.  Mean lipid 
content is not significantly changed between TCDD-treated and control rats, at any time 
post-dose.  There are no statistical differences across time in either species.  This may be 
explained by the great variability in treated mice at 120 hours.  These findings indicate 
that TCDD causes steatosis, or fatty liver, in mice but not rats.  
FIG. 1.  Species comparison of mean lipid weights per gram of liver as a function of time post-
dose.  The legend shows symbols for rat and mouse control and treatment groups.  Effects were 
examined at 72, 120, and 168 hours post-dose.  The asterisk denotes a significant difference in 
treated vs. control mice at the specified time (p≤0.05). See Table 2 for statistical differences 
across time.
Summary of Mean Total Hepatic Lipid Content
To facilitate comparison between mouse and rat, mean hepatic lipid content (mg 
lipid/g liver) for control and treated animals (mice and rats) at each of the three times 
post-dose are summarized in Table 1.  Also indicated are statistical differences between 
control and treated animals at the indicated time post-dose.  A separate table shows the 
statistical differences using the three-factor ANOVA, including time effects (Table 2). 
mg lipid per g of liver
hours post-dose
mg lipid per gram of liver















TABLE 1.  Mean hepatic lipid content in TCDD-treated and vehicle control mice and rats at 72, 120, and 168 h post-dose (Mean ± SE; mg lipid/g 
liver; n=4-5 per group).  The asterisk denotes significant differences (p≤0.05) between TCDD-treated and vehicle control animals at the specified 
time post-dose (one-factor ANOVA with post-hoc Tukey-Kramer HSD). C=control, T=treated, h=hour.
TABLE 2.  Effect-derived differences in mean hepatic lipid content (mg lipid/g liver) for treatment, species, and time.  Statistical significance was 
determined by a three-factor ANOVA testing effect across species, treatment, and time, with JMP statistical software (SAS, Cary, NC, US).  If the 
whole model ANOVA was significant (p≤0.05), then appropriate LSM Differences, HSD, or LSM Differences Student’s t-test was performed. 
Treatment effect shows differences between all animals independent of species, and then within each species (mouse or rat) due to treatment. 
Species effect shows differences between all animals independent of treatment, then within treatment groups (treated or control), based on species. 
Time effect shows differences between the three time-points, between all animals, and then by species.  See Appendix for flowchart of ANOVA 
tests.  M=mouse, R=rat, T=treated, C=control, h=hour post-dose, NS=no significant difference detected, NA=not appropriate.  The p-values are 
not adjusted for multiple testing.
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2.  PCA for Hepatic Lipids in Mice and Rats Analyzed by 13C NMR Spectroscopy
PCA was performed on the combined datasets of mice and rats, and in Figure 2, 
the data separated into three groups:  1) control mice, 2) treated mice, and 3) control and 
treated rats.  There appears to be one outlier:  a control mouse sample, indicated by the 
arrow.  Again, this suggests that TCDD causes steatosis in mice and not rats.
Principal component 1 score
FIG. 2.  PCA of combined rat and mouse datasets.  The legend identifies symbols for rat and 
mouse controls and treated.  The “+” symbols show location of centroid for controls and 
treatments.
3.  Hepatic Lipids Analyzed by 13C NMR Spectroscopy 
Figure 3 shows a representative 13C NMR spectrum of hepatic lipids indicating 
the regions of aliphatic, methyl, and olefinic carbons that come from fatty acids.  The 
solvent signals from CDCl3 and methanol are also identified.  The CDCl3 signal was used 
as a chemical shift reference and set to 77.79 ppm (relative to TSP at 0.0 ppm).  This 
compound was also used for quantification purposes since its concentration in the sample 

















FIG. 3.  Representative 13C NMR spectrum of hepatic lipids showing the location of different 
carbons, for samples in a CDCl3 solution.
TCDD induces changes in mean hepatic lipid metabolites.  The peaks of interest 
in a 13C NMR spectrum of lipid extracts include cholesterol, triacylglycerides (TAGs), 
and n3 and n6 fatty acids (FAs).  An example of a 13C NMR spectrum from a TCDD-
treated mouse liver sample is shown in Figure 4.  The main resonances in the 13C NMR 
spectra of lipids were assigned according to the literature, and these are given in Table 3.
Carbonyl 
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13C NMR Spectrum of Hepatic Lipids
FIG. 4.  An example of a 13C NMR spectrum of lipids from a TCDD-treated mouse liver sample 
at 120 hours.  Abbreviations: TAG, triacylglyceride; FA, fatty acid.
TABLE 3.  Chemical shifts or ranges (on the ppm scale) of common carbon-functional groups 
observed in 13C NMR spectra of mouse and rat liver lipid extracts, referenced to the center peak 
of CDCl3 at 77.79 ppm.  Bold denotes the location of the carbon in the chain represented by that 
peak or peak range.
Chemical shift (ppm) Molecule Assignment
32.0-32.3 n6 FA C5 (C=C-CH2-CH2-CH2-CH2-CH3)
21.0-21.3 n3 FA C2 (-C=C-CH2-CH3)
12.5 Cholesterol methyl group
62.6 TAG 1,3 C on glycerol backbone
Table 4 shows the saturation factors calculated when analyzing the 13C NMR 
spectra of lipid extracts.  NMR was run under fully relaxed (FR), and partially saturated 
(PS) conditions, and integrals for each metabolite of interest was obtained, to calculate 
the saturation factor for each metabolite. 






TABLE 4.  Saturation factors of specific lipid signals analyzed by 13C NMR spectroscopy.  All 
values were expressed as a ratio of integrated intensity relative to the CDCl3 triplet.  FR=fully 
relaxed data, PS=partially saturated data, SF=saturation factor=FR/PS.  
FR PS SF
n3 0.192 2.96 0.0648
n6 0.709 15.8 0.0450
TAG 0.821 29.5 0.0278
Cholesterol 0.0862 3.19 0.0271
PtdC from 13C 0.678 29.2 0.0232
After identifying changes in metabolites from the spectra, and the metabolites 
using previous findings of ppm values from our lab as well as literature, the next step was 
to quantify these levels.  Mean hepatic levels are depicted in graphic form.   
a. Effects of TCDD on Mean Hepatic Triacylglycerides and Cholesterol
1.) Hepatic Triacylglycerides
Figure 5 shows how the mean levels of hepatic triacylglycerides (TAG) change 
over time, in vehicle control and TCDD-treated animals.  The three-factor ANOVA 
shows that the data in the whole model is significant (p<0.0001).  Species and treatment 
are significant, independent of time (p<0.0001).  TAG levels in treated mice are two to 
three-folds higher than levels in controls.  Differences in mean TAG levels in treated vs. 
control rats are not significant (p=0.0937).  
There is a significant time effect (p=0.0350); levels increase from 72 to 168 
hours.  The one-factor ANOVA shows that this increase is in control rats (p=0.0388), and 
that neither group of mice change significantly across time.  The three-factor ANOVA is 
more rigorous than the one-factor ANOVA, so these findings suggest that mean TAG 
levels are significantly higher in TCDD-treated mice than rats.
2.) Hepatic Cholesterol
According to the three-factor ANOVA, the data in the whole model for mean 
cholesterol levels shows significant changes (p=0.0384).  The analysis indicates that 
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species and treatment groups show significant differences (p=0.0505), but not over time 
(p=0.1703).  Significant changes in mean cholesterol levels occur in control and treated 
mice, but not rats (Figure 5).  Mean cholesterol levels in TCDD-treated mice are 21-39% 
higher than levels in control mice at all times post-dose.  The one-factor ANOVA shows 
that TCDD-treated mice have 39% higher mean levels of cholesterol compared to control 
mice at 72 hours (p=0.0132).  Thus, TCDD induces an increase in cholesterol in mice but 
not rats. 
                                Mouse         Rat
FIG. 5.  Mean hepatic triacylglycerides and cholesterol levels (µmol/g liver; mean ± SE; n=4-5) 
measured by 13C NMR spectroscopy in mice and rats as a function of time post-dose with TCDD. 
Empty boxes represent vehicle controls, and filled boxes treated animals.  Bars represent ± 
standard error from the mean.  The asterisk denotes a significant difference in treated vs. control 
























































































b. Effects of TCDD on Mean Hepatic n3 and n6 Fatty Acids
1.) Hepatic n3 Fatty Acids
The three-factor ANOVA shows that the data in the whole model of hepatic n3 
fatty acids (FAs) is not significantly different (p=0.2665) (Figure 6).  The one-factor 
ANOVA shows that levels of n3 FAs increase by 41% in mice at 72 hours (p=0.0127). 
There was no significant effect on hepatic n3 FAs in rats.  
2.) Hepatic n6 FAs
The data in the whole model ANOVA of hepatic n6 FAs is significant, according 
to the three-factor ANOVA (p=0.0049).  The only significant change in mean levels 
occurs between control and treated animals (p<0.0001) (Figure 6).  This test does not 
indicate in which species or at what time post-dose.  Mean levels of n6 FAs are 
significantly higher in treated animals relative to controls.  The one-factor ANOVA 
shows that TCDD induces changes in mean levels of this metabolite in both rats and 
mice.  Mean levels of n6 FAs in TCDD-treated mice relative to controls are 57% higher 
at 72 hours and 36% higher at 168 hours (p=0.0028).  Rats at 120 hours have 41% higher 
mean levels compared to controls (p=0.0246).  There is great variability in treated mice at 
120 hours, which may explain why the time effect was not significant (p=0.1259).  The 
three-factor ANOVA may show a significant species effect if the number of mice, or n, 
were increased.  The analyses show that TCDD affects mean hepatic levels of this 
metabolite in both mice and rats. 
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                                Mouse         Rat
FIG. 6.  Mean hepatic n3 and n6 fatty acids levels (µmol/g liver; mean ± SE; n=4-5) measured by 
13C NMR spectroscopy in mice and rats as a function of time post-dose with TCDD.  Empty 
boxes represent vehicle controls, and filled boxes treated animals.  Bars represent ± standard 
error from the mean.  The asterisk denotes a significant difference in treated vs. control at the 
specified time (p≤0.05).  See Table 6 for statistical differences across time.
Summary of Lipid Quantities Analyzed by 13C NMR Spectroscopy
Table 5 summarizes the quantities of hepatic lipid metabolites analyzed by 13C 
NMR spectroscopy.  These quantities are mean levels, in µmol/g liver, obtained at each 
time post-dose and between treatment groups.  Mean levels in treated and vehicle control 
rats and mice can be compared directly from this table.  Table 6 shows the significant 
















































































TABLE 5. Mean levels of hepatic lipid metabolites measured by 13C NMR spectroscopy from TCDD-treated and vehicle control mice and rats at 
72, 120, and 168 h post-dose (Mean ± SE; µmol/g liver; n=4-5 per group).  The asterisk denotes significant differences (p≤0.05) between TCDD-
treated and vehicle control animals at the specified time post-dose (one-factor ANOVA with post-hoc Tukey-Kramer Honestly Significant 





72 h 120 h 168 h
C T C T C T
TAG 4.87 ±  0.705 16.1 ±  1.01* 6.95 ±  1.15 15.4 ±  3.41* 7.75 ±  1.57 19.4 ±  1.35*
Cholesterol 4.07 ±  0.436 5.67 ±  0.259* 3.98 ±  0.211 5.07 ±  0.975 4.19 ±  0.385 5.05 ±  0.261
n3 FA 4.60 ±  0.565 6.47 ±  0.155* 4.77 ±  0.457 6.25 ±  1.26 7.30 ±  1.71 7.14 ±  1.32




72 h 120 h 168 h
C T C T C T
TAG 5.14 ± 0.465 7.79 ± 1.41 6.72 ± 0.710 10.4 ± 1.95 8.46 ± 1.10 10.1 ± 1.08
Cholesterol 3.84 ± 0.335 4.39 ± 0.168 3.74 ± 0.271 3.88 ± 0.346 5.03 ± 0.490 4.83 ± 0.308
n3 FA 5.55 ±  0.215 5.88 ±  0.516 4.87 ±  0.399 6.60 ±  0.783 6.32 ±  0.508 6.19 ±  0.622
n6 FA 28.6 ± 1.98 32.1 ± 2.91 28.0 ± 0.871 39.4 ± 4.34* 34.9 ± 2.91 37.5 ± 1.99
TABLE 6.  Effect-derived differences in mean levels of specific hepatic lipids measured by 13C NMR spectroscopy (µmol/g liver) for treatment, 
species, and time.  Statistical significance was determined as in Table 2.  n3 FAs did not show significant differences.  M= mouse, R=rat, 
































T > C 
21-39%
(p=0.0505)
NS NS NS NS NS NS NS
n6 FA
T > C 
(p<0.00
01)
NS NS NS NS NS NS NS NS
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4.  Hepatic Phospholipids Analyzed by 31P NMR Spectroscopy
Analysis of 31P NMR spectra provided changes in phospholipids such as 
sphingomyelin (SphM), cardiolipin, phosphatidylethanolamine (PtdE), and 
phosphatidylserine (PtdS). 
31P NMR Spectrum of Hepatic Phospholipids
An example of a 31P NMR spectrum of lipids is shown in Figure 7, from a TCDD-
treated mouse liver sample at 72 hours post-dose.  The locations of phospholipids 
analyzed in this study are indicated.  Each peak represents the phosphate group on the 
phospholipids.  The main resonances in the 31P NMR spectra of lipids were assigned 
according to the literature, and these are given in Table 7.
FIG. 7.  Representative 31P NMR spectrum of liver phospholipids in a TCDD-treated mouse liver 
sample #17, at 72 hours.  Abbreviations: PtdE, phosphatidylethanolamine; SphM, sphingomyelin; 
PtdS, phosphatidylserine; LPC, lysophosphatidylcholine; PtdI, phosphatidylinositol; PtdC, 
phosphatidylcholine. 
TCDD-Treated Mouse 









TABLE 7.  Chemical shifts (on the ppm scale) of phosphates in phospholipids observed in mouse 
and rat liver lipid extracts in 31P NMR spectra, referenced to PtdC at -0.84 ppm.








Table 8 shows the saturation factors calculated when analyzing the 13P NMR 
spectra of lipid extracts. 
TABLE 8.  Saturation factors of specific lipid signals analyzed by 31P NMR spectroscopy.  All 
values were expressed as a ratio of integrated intensity relative to CDCl3.  FR=fully relaxed data, 






a. Effects of TCDD on Mean Hepatic Cardiolipin and Phosphatidylserine
1.) Hepatic Cardiolipin
The three-factor ANOVA shows that the data in the whole model of mean hepatic 
cardiolipin levels is significant (p=0.0269).  Only vehicle control and TCDD-treated 
animals show significant changes in mean levels, independent of species or time 
(p=0.0004).  Both treated animals have significantly lower, and similar, mean levels of 
cardiolipin compared to vehicle controls (Figure 8).  The one-factor ANOVA shows that, 
at 168 hours, mean levels decrease by ca. 20% in both rats and mice (p=0.0113, 0.0320). 
The one-factor ANOVA reveals that mean levels do not change over time, in either mice 
or rats.  Again, the great variability at 120 hours in treated mice may explain why no 
significant changes occurred over time (p=0.1968).
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2.) Hepatic Phosphatidylserine
The data in the whole model of phosphatidylserine (PtdS) levels is significant 
(p=0.0040), using the three-factor ANOVA.  Analysis of species, time, and treatment 
together show significant changes in mean PtdS levels (p=0.0522) (Figure 8).  TCDD-
treated rats have lower mean levels than control rats.  The one-factor ANOVA across 
treatment shows that only rats exhibit significant changes; at 168 hours, mean PtdS levels 
are 43% lower in treated rats than in controls (p=0.0133).  Also, control rats at 168 hours 
have significantly different mean levels from TCDD-treated rats at 72 and 120 hours; 
however, these are not different from treated rats at 168 hours.  Mean hepatic levels in 
control rats at 168 hours and treated mice also differ significantly, but this comparison is 
irrelevant.  Thus, only rats exhibit significantly lowered levels of mean PtdS levels with 
treatment at 168 hours post-dose.  This metabolite was not present in the NMR spectra 
for every animal, so some groups had an n-value of only three.
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                                Mouse         Rat
FIG. 8.  Mean hepatic cardiolipin and phosphatidylserine levels (µmol/g liver; mean ±SE; n=3-5) 
measured by 31P NMR spectroscopy in mice and rats as a function of time post-dose with TCDD. 
Empty boxes represent vehicle controls, and filled boxes treated animals.  Bars represent ± 
standard error from the mean.  The asterisk denotes a significant difference in treated vs. control 
at the specified time (p≤0.05).  See Table 10 for statistical differences across time.
b. Effects of TCDD on Mean Hepatic Phosphatidylcholine and 
Phosphatidylethanolamine
1.) Hepatic Phosphatidylcholine
The three-factor ANOVA shows that the data in the whole model of hepatic 
phosphatidylcholine (PtdC) is not significant (p=0.2975) (Figure 9).  The one-factor 
ANOVAs also show no significant differences in mean hepatic PtdC levels across 
treatment or time in either mice or rats.  Thus, TCDD does not affect mean levels of PtdC 





















































































2.) Hepatic Phosphatidylethanolamine 
The data in the whole model of hepatic phosphatidylethanolamine (PtdE) is 
significant (p=0.0329).  TCDD lowers mean PtdE levels to a greater extent in mice than 
in rats (p=0.0029) (Figure 9).  However, this test does not indicate which treatment group 
exhibits this species effect.  There is also a significant treatment effect (p=0.0097).  Mean 
levels in TCDD-treated animals are lower than control levels, independent of species or 
time.  TCDD-treated mice exhibit 27% lower mean levels of hepatic PtdE relative to 
controls only at 168 hours (p=0.0261). 
                                Mouse         Rat
FIG. 9.  Mean hepatic phosphatidylcholine and phosphatidylethanolamine levels (µmol/g liver; 
mean ± SE; n=4-5) measured by 31P NMR spectroscopy in mice and rats as a function of time 
post-dose with TCDD.  Empty boxes represent vehicle controls, and filled boxes treated animals. 
Bars represent ± standard error from the mean.  The asterisk denotes a significant difference in 




















































































c. Effects of TCDD on the Mean Hepatic PtdC/PtdE Ratio 
The PtdC/PtdE ratio was examined across time in both control and TCDD-treated 
species, and is illustrated in Figure 10.  By the three-factor ANOVA, the data in the 
whole model is significant (p<0.0001).  Significant differences occur with treatment and 
time (p=0.0449), and also with species (p=0.0259).  The mean ratio in treated animals at 
168 hours differs significantly from those at 72 and 120 hours.  The mean ratio in treated 
animals at 168 hours is also different compared to that of controls at all times.  However, 
this test does not indicate in which species these changes occur.  The one-factor ANOVA 
shows that the ratio significantly increases in mice across treatment, by 17% at 72 
(p=0.0005) and 23% at 120 hours (p=0.0002).  There is great variability in the ratio in 
TCDD-treated mice at 168 hours.  One animal had an almost two-fold higher ratio than 
the other animals in the same group (higher PtdC, lower PtdE), and this may explain this 
variability.  Rats show significant changes in the ratio across treatment (12-22%) as well 
as across time (p=0.0029, 0.0007, 0.0023).
The species effect shows that the mean ratio is significantly greater in rats than 
mice.  The one-factor ANOVA shows that the mean ratio in both control mice (p=0.0027) 
and treated rats (p=0.0384) significantly changes across time.  Overall, TCDD causes an 
increase in the PtdC/PtdE ratio in both rats and mice, and it appears that the effect is of 
equal magnitude.
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                                Mouse         Rat
FIG. 10.  TCDD-induced changes in the mean hepatic PtdC/PtdE ratio in mice and rats over time 
(mean ± SE; n=4-5).  Empty boxes represent vehicle controls, and filled boxes treated animals. 
Bars represent ± standard error from the mean.  The asterisk denotes a significant difference in 
treated vs. control at the specified time (p≤0.05).  See Table 10 for statistical differences across 
time.
d. Effects of TCDD on the Mean Hepatic PtdS/PtdE Ratio 
The PtdS/PtdE ratio was analyzed only in rats, and the one-factor ANOVA shows 
treatment and time effects.  In treated rats at 168 hours, the ratio decreases by 36% 
relative to control rats (p=0.0234) (Figure 11).  Control rats show a significant time effect 
(p=0.0125).  As noted earlier, PtdS was not visible in the NMR spectra of each animal, 
and some groups only had three animals (n-value) for analysis.
FIG. 11.  TCDD-induced changes in the mean hepatic PtdS/PtdE ratio in rats over time (mean ± 
SE; n=3-5).  Empty boxes represent vehicle controls, and filled boxes treated animals.  Bars 
represent ± standard error from the mean.  The asterisk denotes a significant difference in treated 














































e. Effects of TCDD on Mean Hepatic Sphingomyelin 
The data in the whole model of hepatic sphingomyelin (SphM) levels is 
significant (p=0.0008), using the three-factor ANOVA.  Species and treatment are 
significant (p=0.0041).  Control and treated rats have different mean SphM levels, 
independent of time (Figure 12).  Mean SphM levels in treated rats are 30-38% lower 
relative to control rats at all times.  The one-factor ANOVA of treatment effects shows 
that TCDD-treated rats at 72 and 168 hours exhibit 30 and 38% lower mean levels of 
SphM relative to control rats, respectively.  Mice do not show significant treatment 
effects.  
The three-factor ANOVA shows a significant time effect (p=0.0031), at 72 and 
120 hours, as well as at 120 and 168 hours.  The one-factor ANOVA shows that mean 
levels in treated mice and control and treated rats significantly change across time.  Mean 
SphM levels in treated mice decrease from 72 to 120 hours (p=0.0415), control rats 
increase from 120 to 168 hours (p=0.0288), and treated rats increase from 72 to 168 and 
120 to 168 hours (p=0.0377). 
                                Mouse         Rat
FIG. 12.  Mean hepatic sphingomyelin levels (µmol/g liver; mean ± SE; n=4-5) measured by 31P 
NMR spectroscopy in mice and rats as a function of time post-dose with TCDD.  Empty boxes 









































the mean.  The asterisk denotes a significant difference in treated vs. control at the specified time 
(p≤0.05).  See Table 10 for statistical differences across time.
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Summary of Phospholipid Quantities Analyzed by 31P NMR Spectroscopy
Table 9 summarizes the quantities of lipid metabolites analyzed by 31P NMR 
spectroscopy.  These quantities are mean levels of specific phospholipids, in µmol/g 
liver, obtained at each time post-dose and between treatment groups.  Table 10 shows the 
significant differences across time, in mean levels of these metabolites.
TABLE 9.  Mean levels of hepatic lipid metabolites measured by 31P NMR spectroscopy from TCDD-treated and vehicle control mice and rats at 
72, 120, and 168 h post-dose (Mean ± SE; µmol/g liver; n=4-5 per group).  Also shown is the PtdC/PtdE ratio for mice and rats.  The asterisk 
denotes significant differences (p≤0.05) between TCDD-treated and vehicle control animals at the specified time post-dose (one-factor ANOVA 





72 h 120 h 168 h
C T C T C T
Cardiolipin 1.01 ±  0.127 0.942 ±  0.0768 1.06 ±  0.0463 0.742 ±  0.163 1.21 ±  0.0605 0.980 ±  0.0182*
PtdS 0.429 ± 0.0674 0.401 ± 0.0706 0.303 ± 0.0328 0.206 ± 0.0396 0.311 ± 0.0474 0.415 ± 0.0540
PtdC 13.8 ± 1.59 15.9 ±  0.970 13.3 ±  0.780 12.7 ±  2.67 15.1 ±  0.598 16.3 ±  0.559
          PtdE 7.01 ±  0.816 6.98 ±  0.527 7.13 ±  0.432 5.49 ± 1.13 7.70 ± 0.255 5.64 ± 0.654*
PtdC/PtdE 1.96 ±  0.0184 2.29 ±  0.0557* 1.87 ±  0.0133 2.31 ±  0.0681* 1.96 ±  0.0189 3.08 ±  0.566





72 h 120 h 168 h
C T C T C T
Cardiolipin 0.967 ± 0.0874 0.855 ± 0.0474 0.971 ± 0.0532 0.746 ± 0.120 1.03 ± 0.0792 0.778 ± 0.0305*
PtdS 0.319 ± 0.0858 0.235 ± 0.0631 0.289 ± 0.00530 0.246 ± 0.0321 0.577 ± 0.0479 0.330 ± 0.0329*
PtdC 12.5 ± 0.833 13.3 ± 0.438 12.5 ± 0.474 13.3 ± 1.09 14.7 ± 1.03 15.3 ± 0.563
         PtdE 5.62 ± 0.424 5.31 ± 0.196 5.62 ± 0.178 5.19 ± 0.450 6.42 ± 0.494 5.48 ± 0.346
PtdC/PtdE 2.24 ± 0.0478 2.51 ± 0.0420* 2.23 ± 0.0283 2.57 ± 0.0580* 2.30 ± 0.0376 2.80 ± 0.112*
PtdS/PtdE 0.0528 ± 0.0125 0.0443 ± 0.0115 0.0514 ± 0.00241 0.0500 ± 0.00979 0.0914 ± 0.00705 0.0583 ± 0.00604*
SphM 0.840 ± 0.108 0.522 ± 0.0696* 0.728 ± 0.0863 0.502 ± 0.0679 1.15 ± 0.104 0.807 ± 0.0941*
TABLE 10.  Effect-derived differences in mean levels of specific hepatic phospholipids measured by 31P NMR spectroscopy (µmol/g liver) for 
treatment, species, and time.  Also shown are differences in the PtdC/PtdE ratio.  Statistical significance was determined as in Table 2.  PtdC and 
PtdI did not show significant differences.  PtdS showed significant, but seemingly irrelevant differences, between control rat at 168 h vs. treated rat 
at 72 h, treated rat at 120 h, and treated mouse at 120 h.  SphM also showed significant differences between treatment, time, and species.  At 72 h, 
SphM levels differed between control mouse and rat, treated mouse and rat, and control and treated mouse.  Also, treated mouse at 72 h were 
different from 120 and 168 h. Treated mouse and rats differed at 168 h.  M= mouse, R=rat, T=treated, C=control, h=hour post-dose, NS= no 


















T < C 
(p=0.0004)
NS NS NS NS NS NS NS NS
PtdE
T < C 
(p=0.0097)
NS NS
M > R 
(p=0.0029)
NS NS NS NS NS
PtdC/PtdE NS NS NS
M < R
(p=0.0259)
NS NS NS NS NS
SphM NA NS













B.  AQUEOUS EXTRACTS
TCDD also induces changes in hepatic aqueous metabolites.  The metabolite 
profiles in aqueous samples were analyzed by 1H and 31P NMR spectroscopy.  31P NMR 
spectra of aqueous extracts yielded amounts of glucose-6-phosphate (G6P), 
glycerophosphocholine (GPC), glycerophosphoethanolamine (GPE), phosphocholine 
(Pcho), phosphoethanolamine (Peth), and glycerol-3-phosphate (G3P).  
1.  Effects of TCDD on Mean Total Hepatic Aqueous Extracts 
Figure 13 shows how the content of dried extract from the aqueous phase of the 
liver extract (mg aqueous/g liver) changes in vehicle control and TCDD-treated animals 
at each time post-dose.  However, most of the weight is likely salts.  The data in the 
whole model is significant when using the three-factor ANOVA (p=0.0011) (Figure 13). 
Species, time, and treatment together are significant (p=0.0182).  At 72 hours, control 
mice have 59% higher mean aqueous content than control rats.  Control mice at this time 
have great variability, due to one mouse liver sample (control #12) having unusually 
higher mean aqueous content than the rest in the same group.  
When conducting the one-factor ANOVA across treatment, with this control 
mouse liver sample #12 included, the treatment effect is not significant (p=0.0965). 
However, when this sample is omitted, mice show significant changes in mean content 
between control and treatment at 72 (p=0.0182) and 120 hours (p=0.0178), and rats at 
168 hours (p=0.0367).  Also, the one-factor ANOVA shows that mean aqueous content in 
treated mice (p=0.0394) and control rats (p=0.0054) significantly changes over time. 
Control mouse liver sample #12 (72 hours post-dose) was removed from the statistical 
analyses when examining significant changes in metabolites from the aqueous extracts.
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FIG. 13.  Species comparison of the mean aqueous extract weights per gram of liver as a function 
of time post-dose.  The legend shows symbols for rat and mouse control and treatment groups. 
Effects were examined at 72, 120, and 168 hours post-dose.  The asterisk denotes a significant 
difference in treated vs. control mice, and double-hatched cross in treated vs. control rats, at the 
specified time (p≤0.05). See Table 9 for statistical differences over time.
Summary of Mean Total Hepatic Content of Aqueous Extract
Mean hepatic content of aqueous extracts for control and treated animals (mice 
and rats) at each of the three times post-dose are summarized in Table 11.  The table also 
shows whether control vs. treated mice or rats were significant at each time post-dose.  
mg aqueous extract per g of liver

















TABLE 11.  Mean hepatic content of aqueous extract in TCDD-treated and vehicle control mice and rats at 72, 120, and 168 h post-dose (Mean ± 
SE; mg aqueous content/g liver; n=3-5 per group).  The asterisk denotes significant differences (p≤0.05) between TCDD-treated and vehicle 





72 h 120 h 168 h
C T C T C T
Aqueous Content
(mg aq/g liver)
35.2±2.09 29.1±0.751* 33.4±0.858 39.1±1.51* 36.9±2.72 33.3±3.89
Rat
72 h 120 h 168 h
C T C T C T
Aqueous Content
(mg aq/g liver)
26.3±0.335 29.6±1.63 26.8±0.947 27.8±1.01 35.6±2.78 28.3±0.946*
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2.  Hepatic Metabolites Analyzed by 31P NMR Spectroscopy of Aqueous Extracts
There was one mouse liver sample (control mouse #32), at the 168-hour time-
point that needed to be removed from the 31P NMR spectroscopy analysis of aqueous 
extracts.  Several peaks were broadened, and it is believed to be due to paramagnetic 
cations remaining in the sample not completely removed by the chelex.  Unfortunately, 
this lowered the n-value for control mice at the 168-hour post-dose to three.
31P NMR Spectrum of Hepatic Aqueous Metabolites
An example of a 31P NMR spectrum of aqueous metabolites from a treated mouse 
liver is shown in Figure 14.  Table 12 shows the chemical shifts of metabolites identified 
in the 31P NMR spectra of aqueous extracts.  All 31P NMR spectra were referenced to 
GPC at 3.082 ppm.  Metabolites were identified using ppm values obtained from the 
literature. 
FIG. 14.  31P NMR spectrum of aqueous metabolites in a TCDD-treated rat liver sample at 72 
hours.  Abbreviations:  DHAP, dihydroxyacetone phosphate; G6P, glucose-6-phosphate; G3P, 










TABLE 12.  Chemical shifts (on the ppm scale) of phosphates observed in mouse and rat in 31P 
NMR spectra of aqueous liver extracts, referenced to GPC at 3.082 ppm. 










Table 13 shows the saturation factors calculated when analyzing the 13P NMR 
spectra of aqueous extracts. 
TABLE 13.  Saturation factors of specific aqueous metabolite signals analyzed by 31P NMR 
spectroscopy.  All values were expressed as a ratio of integrated intensity relative to MDPA for 
31P NMR spectroscopy.  FR=fully relaxed data, PS=partially saturated data, SF=saturation 
factor=FR/PS.  
31P metabolite FR PS SF
DHAP 2.05 1.34 1.53
G6P 5.14 4.86 1.06
G3P 19.4 16.5 1.18
Pcho 30.1 25.1 1.20
Peth 4.98 4.25 1.17
GPC 2.60 2.73 0.954
GPE 4.12 4.18 0.986
a. Effects of TCDD on Mean Hepatic DHAP and Glycerol-3-Phosphate
1.) Hepatic DHAP
When using the three-factor ANOVA to examine whether significant changes 
occur in mean levels of hepatic DHAP, the data in the whole model is not significant 
(p=0.2912) (Figure 15).  However, the one-factor ANOVA shows that mean DHAP 
levels in TCDD-treated mice are 49% lower than in control mice at 168 hours 
(p=0.0469).  No significant changes occur across time in either species.
2.) Hepatic Glycerol-3-Phosphate
The data in the whole model for glycerol-3-phosphate (G3P) is significant, 
according to the three-factor ANOVA (p=0.0024).  There is a significant species and time 
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effect (p=0.0095), but differences between treatment are not significant (p=0.4919) 
(Figure 15).  In mice, levels of G3P significantly decrease from 120 to 168 hours.  Mean 
hepatic G3P levels in mice at 120 hours also differ from rats at each time post-dose, but 
this is irrelevant.  The one-factor ANOVA shows no significant changes in either species 
across treatment.  However, there is a significant time effect in treated mice (p=0.0177).  
                                Mouse         Rat
FIG. 15.  Mean hepatic DHAP and glycerol-3-phosphate levels (µmol/g liver; mean ± SE; n=3-5) 
measured by 31P NMR spectroscopy in mice and rats as a function of time post-dose with TCDD. 
Empty boxes represent vehicle controls, and filled boxes treated animals.  Bars represent ± 
standard error from the mean.  The asterisk denotes a significant difference in treated vs. control 
at the specified time (p≤0.05).  See Table 15 for statistical differences across time.
b. Effects of TCDD on the Mean Hepatic G3P/DHAP Ratio
Figure 16 shows how the mean G3P/DHAP ratio varies across time in each 
species.  The reduced/oxidized form of the ratio provides information about the cytosolic 






















































































significant (p=0.0038).  There is only a significant species effect (p=0.0005); mice appear 
to have higher mean ratios than rats.  This species effect is independent of treatment or 
time.  The one-factor ANOVAs across treatment or time prove not significant.  
                                Mouse         Rat
FIG. 16.  TCDD-induced changes in the G3P/DHAP ratio measured by 31P NMR spectroscopy in 
mice and rats as a function of time post-dose with TCDD (mean ± SE; n=3-5).  Empty boxes 
represent vehicle controls, and filled boxes treated animals.  Bars represent ± standard error from 
the mean.  The asterisk denotes a significant difference in treated vs. control at the specified time 
(p≤0.05).  See Table 15 for statistical differences across time.
c. Effects of TCDD on Mean Hepatic Glucose-6-Phosphate
The data in the whole model for hepatic glucose-6-phosphate (G6P) levels shows 
significant TCDD-induced effects (p=0.0112).  There is a significant treatment effect, 
mean levels of G6P falling after administration of TCDD (p=0.0066) (Figure 17).  There 
is also a significant species effect (p=0.0019).  According to the one-factor ANOVA, at 
120 hours, mean G6P levels in treated rats are 29% lower than mean levels in control rats 
(p=0.0321).  Control and treated mice are not significantly different, perhaps due to 
control mice showing greater variability at 120 hours.  The analysis also shows that mean 



























                                Mouse         Rat
FIG. 17.  Mean hepatic glucose-6-phosphate levels (µmol/g liver; mean ± SE; n=3-5) measured 
by 31P NMR spectroscopy in mice and rats as a function of time post-dose.  Empty boxes 
represent vehicle controls, and filled boxes treated animals.  Bars represent ± standard error from 
the mean.  The asterisk denotes a significant difference in treated vs. control at the specified time 
(p≤0.05).  See Table 15 for statistical differences across time. 
d. Effects of TCDD on Mean Hepatic Phosphocholine and Phosphoethanolamine
1.) Hepatic Phosphocholine
The three-factor ANOVA shows the data in the whole model for hepatic 
phosphocholine (Pcho) (p<0.0001).  There is a significant species and treatment effect, 
independent of time (p<0.0001).  Figure 18 clearly shows that the mean Pcho levels are 
different between control and treated rats.  Mean Pcho levels are 2.6-3.2-folds higher in 
TCDD-treated rats than those in control rats, at all times post-dose.  The one-factor 
ANOVA shows that in rats, mean Pcho levels are significantly different between control 
and treated groups at all times (p=0.0052, <0.0001, <0.0001).  This treatment effect is not 
observed in mice.
These findings indicate that TCDD greatly induces mean Pcho levels in rats and 
not mice.  The three-factor ANOVA shows no significant time effects (p=0.9690), 
however, the one-factor analysis shows that mean Pcho levels in treated mice differ 









































The data in the whole model of hepatic phosphoethanolamine (Peth) shows 
significant differences (p=0.0229).  Significant changes occur with species, time, and 
treatment together (p=0.0118), but the Tukey test failed to specify which factor (Figure 
18).  The Tukey test may show significant effects if the n-value is increased.
The one-factor ANOVA shows that mean Peth levels significantly change 
between control and treated rats at 120 hours (p=0.0229).  Levels in treated rats are 20% 
lower than levels in control rats.  Only TCDD-treated mice change over time (p=0.0042). 
                                Mouse         Rat
FIG. 18.  Mean hepatic phosphocholine and phosphoethanolamine levels (µmol/g liver; mean ± 
SE; n=3-5) measured by 31P NMR spectroscopy in mice and rats as a function of time post-dose. 
Empty boxes represent vehicle controls, and filled boxes treated animals.  Bars represent ± 
standard error from the mean.  The asterisk denotes a significant difference in treated vs. control 






















































































e. Effects of TCDD on Mean Hepatic Glycerophosphocholine and 
Glycerophosphoethanolamine
1.) Hepatic Glycerophosphocholine
The three-factor analysis of mean glycerophosphocholine (GPC) levels shows that 
the data in the whole model is significant (p=0.0020).  Significant changes occur with 
treatment and species (p=0.0465), but these comparisons are irrelevant (control rats vs. 
control mice, and treated rats vs. control mice) (Figure 19).  There is no significant time 
effect (p=0.1315). 
The one-factor ANOVA shows that only at the 168-hour time post-dose, GPC 
levels in treated mice are significantly lower (26%) than those in control mice 
(p=0.0334).  Time effects are not significant in either species.
2.) Hepatic Glycerophosphoethanolamine
Analysis of mean glycerophosphoethanolamine (GPE) levels using the three-
factor ANOVA shows that the data in the whole model is significant (p<0.0001).  There 
is only a significant species effect, independent of treatment or time (Figure 19).  Mean 
levels of this metabolite are greater in rats than in mice (p<0.0001). 
The one-factor ANOVA shows that mean GPE levels do not change significantly 
across treatment in either species, and that treated mice show a significant effect across 
time (p=0.0072). 
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                                Mouse         Rat
FIG. 19.  Mean hepatic glycerophosphocholine and glycerophosphoethanolamine levels (µmol/g 
liver; mean ± SE; n=3-5) measured by 31P NMR spectroscopy in mice and rats as a function of 
time post-dose.  Empty boxes represent vehicle controls, and filled boxes treated animals.  Bars 
represent ± standard error from the mean.  The asterisk denotes a significant difference in treated 
vs. control at the specified time (p≤0.05).  See Table 15 for statistical differences across time. 
Summary of Metabolite Quantities Analyzed by 31P NMR Spectroscopy of Aqueous 
Extracts
Table 14 summarizes the mean quantities of metabolites analyzed by 31P NMR 
spectroscopy of hepatic aqueous extracts, in µmol/g liver.  This is to facilitate species 















































































TABLE 14.  Mean levels of hepatic metabolites measured by 31P NMR spectroscopy of aqueous extracts from TCDD-treated and vehicle control 
mice and rats at 72, 120, and 168 hours post-dose (Mean ± SE; µmol/g liver; n=3-5 per group).  Also shown is the G3P/DHAP ratio for mice and 
rats.  The asterisk denotes significant differences (p≤0.05) between TCDD-treated and vehicle control animals at the specified time post-dose (one-





72 h 120 h 168 h
C T C T C T
DHAP 0.536±0.202 0.271±0.0288 0.316±0.0505 0.337±0.0762 0.439±0.0849 0.208±0.0517*
G3P 3.09±0.143 2.81±0.221 3.66±0.720 3.62±0.382 2.69±0.476 2.20±0.258
G3P/DHAP 9.28±2.44 10.6±0.497 12.1±1.91 11.9±1.62 7.04±2.48 12.6±2.40
G6P 0.937±0.123 0.711±0.0495 1.14±0.250 0.940±0.0971 0.914±0.194 0.636±0.0952
         Pcho 0.778±0.0789 0.676±0.103 1.10±0.266 1.24±0.141 0.778±0.202 0.946±0.111
         Peth 0.669±0.0340 0.558±0.0538 0.755± 0.143 0.864±0.0767 0.565±0.0458 0.549±0.0451
GPC 0.464±0.0689 0.307±0.0543 0.371±0.0719 0.354±0.0217 0.324±0.0119 0.240±0.0219*




72 h 120 h 168 h
C T C T C T
DHAP 0.323±0.0233 0.417±0.0586 0.306±0.0297 0.360±0.0246 0.392±0.0537 0.332±0.0306
G3P 2.21±0.0822 2.52±0.278 2.45±0.148 2.30±0.116 2.48±0.116 2.45±0.136
G3P/DHAP 6.94±0.476 6.27±0.637 8.29±0.845 6.59±0.723 6.69±0.686 7.61±0.675
G6P 0.687±0.0721 0.691±0.0816 0.835±0.0795 0.594±0.0481* 0.686±0.0380 0.627±0.0417
         Pcho 2.98±0.208 9.60±1.72* 3.06±0.287 8.41±0.587* 2.81±0.148 7.33±0.356*
         Peth 0.485±0.0472 0.753±0.134 0.666±0.0437 0.532±0.0195* 0.756±0.130 0.516±0.0717
GPC 0.248±0.0210 0.260±0.0385 0.248±0.0376 0.241±0.0260 0.228±0.0159 0.254±0.0299
GPE 0.292±0.0281 0.307±0.0617 0.239±0.0353 0.250±0.0389 0.217±0.0479 0.256±0.0387
TABLE 15.  Effect-derived differences in mean levels of specific hepatic metabolites measured by 31P NMR spectroscopy of aqueous extracts 
(µmol/g liver) for treatment, species, and time.  Also shown is the G3P/DHAP ratio.  Statistical significance was determined as in Table 2. 
M=mouse, R=rat, T=treated, C=control, h=hours post-dose, NS=no significant difference detected, NA=not appropriate.  The p-values are not 







(72 h vs. 120 h vs. 168 h)
Main Effect 












G3P/DHAP NS NS NS
M < R
(p=0.0005)

























GPE NS NS NS
M < R
(p<0.0001)
NS NS NS NS NS
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f. Effects of TCDD on the Mean Hepatic SphM/Pcho Ratio
Figure 20 shows how the mean SphM/Pcho ratio differs between mice and rats, 
across time.  The three-factor ANOVA shows that the data in the whole model for the 
ratio is significant (p<0.0001).  Species, time, and treatment together are significant 
(p=0.0413).  At 72 hours, the mean ratio in TCDD-treated mice is 1.6-fold higher than 
that in control mice.  The one-factor ANOVA shows that the ratio is significant only at 
72 hours in mice (p=0.0566), and at all times in rats (p=0.0009, 0.0019, 0.0029).  The 
ratio is ca. 76% lower in treated rats relative to control rats, at all times.  There is also a 
significant time effect, in treated mice (p=0.0005) as well as in control (p=0.0484) and 
treated rats (p=0.0369). 
                                Mouse         Rat
FIG. 20.  TCDD-induced changes in the mean hepatic SphM/Pcho ratio in mice and rats over 
time (mean ± SE; n=3-5).  Empty boxes represent vehicle controls, and filled boxes treated 
animals.  Bars represent ± standard error from the mean.  The asterisk denotes a significant 
difference in treated vs. control mice and rats at the specified time (p≤0.05).  
Table 16 summarizes the mean SphM/Pcho ratio in TCDD-treated and vehicle 


























TABLE 16.  Mean SphM/Pcho ratio measured by NMR spectroscopy of liver and aqueous extracts from TCDD-treated and vehicle control mice 
and rats at 72, 120, and 168 hours post-dose (Mean ± SE; n=3-5 per group).  The asterisk denotes significant differences (p≤0.05) between TCDD-
treated and vehicle control animals at the specified time post-dose (one-factor ANOVA with post-hoc Tukey-Kramer Honestly Significant 




72 h 120 h 168 h
C T C T C T
SphM/Pcho 0.915 ± 0.154 1.44 ± 0.175* 0.574 ± 0.162 0.389 ± 0.100 0.777 ± 0.170 0.888 ± 0.0976
Ratio
Rat
72 h 120 h 168 h
C T C T C T
SphM/Pcho 0.289 ± 0.0426 0.0613 ± 0.0121* 0.242 ± 0.0311 0.0622 ± 0.0138* 0.421 ± 0.0614 0.108 ± 0.0101*
54
3.  Hepatic Metabolites Analyzed by 1H NMR Spectroscopy of Aqueous Extracts
Levels of lactate and pyruvate are obtained from the 1H NMR spectra.  The 
analysis includes control mouse #32, since the 1H NMR spectrum did not appear affected 
by the paramagnetic cations that remained in the sample.  Peaks were identified using 
reported literature values, and chemical shifts, in ppm, are indicated in Table 17.
TABLE 17.  Chemical shifts (on the ppm scale) of common hydrogen-functional groups 
observed in mouse and rat liver aqueous extracts in 1H NMR spectra, referenced to TSP at 0.0 
ppm.  Bold denotes the specific hydrogen atom that the peak represents.




Table 18 shows the saturation factors calculated when analyzing the 1H NMR 
spectra of aqueous extracts. 
TABLE 18.  Saturation factors of specific aqueous metabolite signals analyzed by 1H NMR 
spectroscopy.  All values were expressed as a ratio of integrated intensity relative to TSP for 1H 
NMR spectroscopy.  FR=fully relaxed data, PS=partially saturated data, SF=saturation 
factor=FR/PS.  
1H metabolite FR PS SF
Pyruvate 13.1 13.0 1.01
Lactate (4.11 ppm) 18.6 17.4 1.07
Lactate (1.33 ppm) 51.2 52.3 0.979
a. Effects of TCDD on Mean Hepatic Lactate and Pyruvate
1.) Hepatic Lactate
Figure 21 shows how mean hepatic lactate levels change in both rats and mice, 
across time post-dose.  The data in the whole model is significant for mean lactate levels, 
by the three-factor ANOVA (p<0.0001).  Species, time, and treatment together are 
significant (p=0.0343).  In TCDD-treated mice, mean lactate levels significantly increase 
from 72 to 120 hours, and decrease from 120 to 168 hours.  
Analysis of significant treatment effects using the one-factor ANOVA show that 
control and TCDD-treated mice exhibit significant changes only at 72 hours (p=0.0004).  
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At 72 hours, mean lactate levels in treated mice are 30% lower than that in control mice. 
Analysis of effects across time are significant in control and treated mice (p=0.0056, 
0.0043).  Rats exhibit no significant changes in mean lactate levels by either ANOVAs. 
2.) Hepatic Pyruvate
The three-factor ANOVA shows the data in the whole model for mean levels of 
pyruvate is significant (p<0.0001).  Time and species are significant (p=0.0031); 
however, changes across treatment are not (p=0.2727) (Figure 21).  Mean pyruvate levels 
in mice significantly increase from 72 to 120 hours, and decrease from 120 to 168 hours. 
Mice and rats have significantly different mean levels at 72 and 120 hours.  Mice at 120 
hours have significantly higher mean levels than rats at 72 and 168 hours, but not at 120 
hours.  The one-factor ANOVA across treatment is not significant in either species; 
however, treated mice exhibit significant changes across time (p=0.0142). 
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                           Mouse      Rat
FIG. 21.  Mean hepatic lactate and pyruvate levels (µmol/g liver; mean ± SE; n=4-5) measured 
by 1H NMR spectroscopy in mice and rats as a function of time post-dose.  Empty boxes 
represent vehicle controls, and filled boxes treated animals.  Bars represent ± standard error from 
the mean.  The asterisk denotes a significant difference in treated vs. control at the specified time 
(p≤0.05).  See Table 20 for statistical differences across time. 
b. Effects of TCDD on the Mean Hepatic Lactate/Pyruvate Ratio
Figure 22 shows how the lactate/pyruvate ratio changes across time, in both 
species.  This ratio is another indicator of the cytosolic redox potential.  When examining 
the mean ratio using the three-factor ANOVA, the data in the whole model is not 
significant (p=0.3082).  According to mouse data in the figure, this does not make sense.  
The one-factor ANOVAs did indeed find significant effects across treatment in 
mice.  At 72 hours, the mean ratio in TCDD-treated mice is 26% lower than that in 





















































































exhibit significant changes over time.  The mean ratio is not significant across time or 
treatment in rats.
                             Mouse           Rat
FIG. 22.  TCDD-induced changes in the mean hepatic lactate/pyruvate ratio in mice and rats over 
time (mean ± SE; n=4-5).  Bars represent ± standard error from the mean.  The asterisk denotes a 
significant difference in treated vs. control at the specified time (p≤0.05).  See Table 20 for 
statistical differences across time. 
Summary of Metabolite Quantities Analyzed by 1H NMR Spectroscopy of Aqueous 
Extracts
Table 19 summarizes metabolite quantities analyzed by 1H NMR spectroscopy of 
the hepatic aqueous extracts.  These quantities, in µmol/g liver, are mean levels obtained 
at each time post-dose and between treatment groups.  Mean levels in treated and vehicle 
control rats and mice can be compared directly from this table.  Table 20 shows the 

































TABLE 19.  Mean levels of hepatic metabolites measured by 1H NMR spectroscopy of aqueous extracts from TCDD-treated and vehicle control 
mice and rats at 72, 120, and 168 hours post-dose (Mean ± SE; µmol/g liver; n=3-5 per group).  Also shown is the lactate/pyruvate ratio for mice 
and rats.  The asterisk denotes significant differences (p≤0.05) between TCDD-treated and vehicle control animals at the specified time post-dose 
(one-factor ANOVA with post-hoc Tukey-Kramer HSD).  C=control, T=treated, h=hour.
TABLE 20.  Effect-derived differences in mean levels of specific hepatic metabolites measured by 1H NMR spectroscopy of aqueous extracts 
(µmol/g liver) for treatment, species, and time.  Statistical significance was determined as in Table 2.  Lactate showed significant differences 
between treatment, time, and species (see results).  The whole-factor ANOVA was not significant for pyruvate levels, but the two-factor ANOVA 
showed significant changes occurring (see results).  M=mouse, R=rat, T=treated, C=control, h=hours post-dose, NS=no significant difference 





72 h 120 h 168 h
C T C T C T
Lactate 20.1±0.946 14.1±0.409* 19.8±0.988 21.5±1.66 15.1±0.695 12.2±2.31
Pyruvate 3.61±0.292 3.46±0.257 3.81±0.314 5.60±0.781 3.06±0.771 3.03±0.493




72 h 120 h 168 h
C T C T C T
Lactate 11.0±0.360 11.9±1.67 10.8±0.167 10.5±0.908 10.3±0.807 9.46±0.729
Pyruvate 2.30±0.229 2.17±0.238 2.00±0.0441 1.98±0.130 2.22±0.161 2.22±0.179






















This report will elucidate the different metabolic pathways affected by TCDD in 
mice and rats.  Our NMR study of hepatic lipids (TAG, cholesterol, and n3 and n6 FAs) 
showed increased levels in mice but not rats, consistent with PCA results showing 
separation between control and treated mice, and overlapping clusters in rats.  The 
following sections will discuss four possible pathways affected by TCDD:  A) increased 
TAG synthesis in mice, B) increased cholesterol uptake in mice, C) activation of 
sphingomyelinase in rats, and D) mitochondrial damage in both mice and rats. 
Comparisons will be made between these pathways and genomic effects.  
A.  Increased Levels of Hepatic TAG Suggest TAG Synthesis is Upregulated in Mice
 NMR spectroscopy analyses show that mean hepatic levels of TAGs increased 
two to three-folds at all times in TCDD-treated mice (Figure 5).  These increased levels 
may be explained by upregulated TAG synthesis.  TAGs are synthesized from FAs and 
G3P.  FAs esterified with CoA are condensed with the glycerol moiety of G3P to form 
phosphatidic acid (PA).  G3P can be derived from glucose or glycerol or other three-
carbon compounds that are used for gluconeogenesis.  Loss of the phosphate group via 
PA phosphohydrolase yields DAG.  Transfer of another FA acyl-CoA to the glycerol 
backbone, via DAG acyltransferase, yields TAG.  DAG kinase catalyzes the reverse step 
of PA phosphohydrolase. 
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If TAG synthesis is upregulated in TCDD-treated mice, and G3P is utilized for 
TAG synthesis, the G3P-dehydrogenase reaction (a NAD+/NADH-linked dehydrogenase, 
Figure 23) will favor the production of G3P.  This is supported by the finding that DHAP 
levels decreased 49% in TCDD-treated mice (Figure 15).  This decrease in DHAP in 
treated mice may be due to utilization of G3P for TAG synthesis. 
FIG. 23. G3P and lactate dehydrogenase reactions
However, the G3P/DHAP ratio only shows a significant species difference.  The 
ratio is higher in mice than rats (Figure 16).  The shift in the G3P-dehydrogenase 
equilibrium causes a shift in the cytosolic redox potential, decreasing the NADH/NAD+ 
ratio.  Since the lactate-dehydrogenase reaction operates near equilibrium and depends on 
this redox potential, this change in the NADH/NAD+ ratio will drive the lactate-
dehydrogenase reaction towards production of pyruvate.  This, in turn, will cause the 
lactate/pyruvate ratio to decrease.  Indeed, in mice treated with TCDD, the 
lactate/pyruvate ratio significantly decreased ca. 25% at 72 and 120 hours (Figure 22). 
Rats showed no significant changes in the lactate/pyruvate ratio.  Thus, there may be a 
driving force to synthesize G3P for TAG synthesis in treated mice (Figure 24).  
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FIG. 24. Gluconeogenesis, TAG synthesis, and Cholesterol Synthesis in TCDD-Treated 
Mice and Rats.  Metabolites circled were measured by NMR spectroscopy. A rectangle box 
placed adjacent to a metabolite indicates a statistically significant difference in the level of this 
metabolite (treated vs. control; p≤0.05). Information in this box designates: (1) the species that 
showed change (M=mouse; R=rat), (2) whether the metabolite increased or decreased (up or 
down arrow), (3) the magnitude of change (% relative to control), and (4) the designated time-
point (h=hour). Bold arrows indicate pathways possibly upregulated in response to TCDD. Heavy 
gray arrows show transport of metabolites between the cytosol and mitochondrion. The dashed 
line represents the inner mitochondrial membrane. Abbreviations: 1,3BPG, 1,3-
bisphosphoglycerate; ACC, acetyl-CoA carboxylase; αKG, α−ketoglutarate; Asp, aspartate; 
AST, aspartate aminotransferase; CoA, coenzyme A; DAG, diacylglycerol; DAG acyltransferase, 
diacylglycerol acyltransferase; DAG kinase, diacylglycerol kinase; DHAP, dihydroxyacetone 
phosphate; F1,6BP, fructose-1,6-bisphosphate; F1,6-BPase, fructose-1,6-bisphosphatase; F6P, 
fructose-6-phosphate; FA, fatty acid; Fasn, fatty acid synthase; G3P, glycerol-3-phosphate; G3P-
DH, glycerol-3-phosphate dehydrogenase; G6P, glucose-6-phosphate; G6P DH, glucose-6-
phosphate dehydrogenase; GA3P, glyceraldehyde-3-phosphate; GA3P DH, glyceraldehyde-3-
phosphate dehydrogenase; Glu, glutamate; HMG-CoA, hydroxymethylglutaryl CoA; Lac/Pyr, 
lactate/pyruvate ratio; LDH, lactate dehydrogenase; Lyso-PA, lysophosphatidic acid; MDH, 
malate dehydrogenase; NAD+, nicotinamide adenine dinucleotide; NADH, reduced nicotinamide 
adenine dinucleotide OAA, oxaloacetate; PA, phosphatidic acid; PA phosphohydrolase, 
phosphatidic acid phosphohydrolase; PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase; 
PFK, phosphofructokinase; PEP, phosphoenolpyruvate; PEPCK, phosphoenolpyruvate 






























M n3 ↑41% (72h)
M n6 ↑36-57% (72,168h)






























































Another measure of the cytosolic redox potential can come from the 
glyceraldehyde-3-phosphate dehydrogenase reaction.  Neither glyceraldehyde-3-
phosphate nor 1,3-bisphosphoglycerate were measured, but will be done in the future, 
from the 31P NMR spectra.
NMR spectroscopy analyses of hepatic G6P show G6P levels were not affected in 
TCDD-treated mice.  This is consistent with the hypothesized mechanism that 
gluconeogenesis may be occurring to the level of the trioses, and to TAG synthesis.  In 
TCDD-treated rats at 120 hours, levels significantly decreased (by 29%) relative to 
vehicle controls (Figure 17).  This decrease in rats may be explained by inhibited 
gluconeogenesis.  Another possibility is the pentose phosphate pathway.  Reductive 
biosynthesis may be occurring, suggesting a need for NADPH for reducing power. 
TAG Synthesis in Mice – Comparison to Genomic Effects
Work is ongoing to examine mRNA expression or activities of enzymes in the 
TAG synthetic pathway from G3P (PA phosphohydrolase, DAG acyltransferase, and 
DAG kinase), to confirm the upregulation of TAG synthesis in mice.  PA 
phosphohydrolase activity is known to be increased by FAs.  Hepatic levels of FAs are 
elevated in TCDD-treated mice, so it is expected that the activity of this enzyme would 
be upregulated and TAG synthesis is active.
Reports show that the mRNA expression of glucokinase, the enzyme that converts 
glucose to G6P, is inhibited by TCDD in mice and rats (Boverhof et al., 2005; Fletcher et  
al., 2005).  However, its repression in mice occurs at 12 and 24 hours, earlier time-points 
than those observed in this study.  Fletcher and coworkers used male Sprague-Dawley 
rats, administered 40 µg/kg body weight, and reported that the downregulation of 
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glucokinase could explain the altered glucose production and decreased G6P levels in 
TCDD-treated rat liver (Fletcher et al., 2005).  It would be interesting to see what 
happens to messenger levels of this enzyme in mice treated with TCDD, from 72 to 168 
hours.  
The activity of G3P dehydrogenase may be affected in a way that favors the 
synthesis or buildup of G3P, and thus TAG levels in mice.  Also, phosphoenolpyruvate 
carboxykinase might be upregulated.  This enzyme is the rate-limiting step in 
gluconeogenesis from lactate and pyruvate.  However, it is downregulated in mice, at 18 
and 24 hours, earlier time-points than observed in this study (Boverhof et al., 2005, 
2006).  Again, information into what happens at the time-points examined in our study 
could be valuable.  Also, alanine, glutamate, and aspartate levels will be quantified from 
1H NMR spectra of aqueous extracts as future work.
TCDD-Induces Fatty Acid Uptake and Metabolism
NMR spectroscopy analyses show significant increases in mean hepatic levels of 
n3 and n6 FAs with TCDD treatment in mice (Figure 6).  Increased levels of FAs may 
indicate upregulated FA synthesis.  In de novo FA synthesis, the products of glycolysis 
are converted to FAs.  Pyruvate carboxylase releases oxaloacetate, which goes into the 
Krebs Cycle (TCA) to form citrate.  Citrate is then transported to the cytosol where it is 
broken down to oxaloacetate and acetyl-CoA by ATP-citrate lyase.  Acetyl-CoA is 
carboxylated to malonyl-CoA, and FA synthase produces palmitate.  However, palmitate 
does not synthesize n3 or n6 FAs.  Instead, the increased levels of FAs in mice may be 
explained by FA uptake.  Examination into the serum free FA levels support increased 
FA mobilization from adipose tissue to the blood to liver.  Zacharewski and coworkers 
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found, using the same strains of female i.o. rodents as our study, that serum free FA 
significantly increased ca. 22% in TCDD-treated mice from 72 to 168 hours (p<0.05) 
(Boverhof et al., 2006).  This hypothesis is supported by histopathology and microarray 
data.  Hepatic tissue in mice revealed vacuolization due to TAG or FA accumulation (Boverhof et al., 
2006), consistent with reported gene expression findings that mediate increased uptake in mouse.  Such gene 
findings include upregulation of Cd36 antigen (3.4-fold at 168 hours), lipoprotein lipase (3.5-fold at 168 hours), 
Lipin2 (3-fold at 72 hours), and very low-density lipoprotein receptor (1.8-fold at 72 hours).  Null mutations of 
Cd36 antigen result in reduced FA uptake, and overexpression increases FA uptake and metabolism (Bonen 
et al., 2004; Febbraio et al., 1999).  Lipoprotein lipase is involved in TAG metabolism and lipoprotein uptake 
(Weinstock et al., 1995).  Lipin2, when deficient, prevents normal lipid accumulation (Peterfy 
et al., 2001).  Very low-density lipoprotein receptor mediates the degradation of TAG-rich lipoproteins 
(Yagyu et al., 2002).  The regulation of these genes may lead to the increased uptake and accumulation of TAG 
and FA in liver.
The mRNA expression of ATP-citrate lyase in mice remains to be determined. 
Reports have shown that ATP-citrate lyase inhibitors decrease the syntheses of FA and 
cholesterol (Pearce et al., 1998; Sullivan et al., 1974).  It would be interesting to look into 
messenger levels of pyruvate carboxylase in mice as well.
B.  Increased Levels of Hepatic Cholesterol Suggests Cholesterol Uptake in Mice 
This report shows that mean hepatic cholesterol levels significantly increased 21-
39% in TCDD-treated mice relative to control.  Treated vs. control rats show no 
significant differences (Figure 5).  This finding may suggest increased cholesterol 
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synthesis or an increase in the uptake of cholesterol into liver, in treated mice.  In de novo 
synthesis, acetyl-CoA is first converted to mevalonate via acetoacetyl-CoA synthase, 
hydroxymethylglutaryl-CoA (HMG-CoA) synthase, and HMG-CoA reductase.  An 
isoprene unit is formed from mevalonate via mevalonate decarboxylase.  Squalene then 
becomes cholesterol (Figure 24).  
Interestingly, only mice exhibit significant alterations in serum cholesterol, 
decreasing ca. 30% at 72 to 168 hours (p<0.05) (Boverhof et al., 2006).  The finding that 
serum cholesterol decreased and hepatic cholesterol increased by similar amounts, 
suggests that the uptake of cholesterol to liver might be occurring in mice.  
Cholesterol Uptake in Mice – Comparison to Genomic Effects
In mice, mRNA expression for low density lipoprotein receptor-related protein 
was upregulated by three-fold at 72 to 168 hours (Boverhof et al., 2005).  The 
upregulation of this protein may explain the increased levels of hepatic cholesterol and 
reduced serum levels.  To confirm the hypothesis that cholesterol uptake is occurring in 
mice, it would be interesting to examine mRNA expression of HMG-CoA synthase and 
reductase (rate-limiting step) in mouse.  Also, levels of mevalonate can be quantified 
from the 1H NMR spectra.
C. Activation of Sphingomyelinase in Rats
In TCDD-treated rats, mean hepatic SphM levels are 30-38% lower than controls 
at 72 and 168 hours, and not significantly changed in mice (Figure 12).  SphM is a 
phospholipid involved in development and differentiation, the cellular response to 
cytokines, and apoptosis (Dressler et al., 1992; Hannun 1994, 1996; Hannun and Obeid, 
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1995; Obeid and Hannun, 1995).  TCDD-treated rats have significantly higher levels of 
Pcho (ca. three-fold relative to control) (Figure 18).  
The activation of sphingomyelinase results in a buildup of Pcho and ceramide, 
and the SphM and Pcho data in rats are consistent with this pathway (Figure 25).  SphM 
turnover to ceramide mediates the cellular response to tumor necrosis factor (TNF-α). 
The decreased SphM/Pcho ratio in treated rats at all times suggests that TCDD induces 
the activation of sphingomyelinase, possibly through TNF-α (Figure 20).  Also 
interesting are the findings that the SphM/Pcho ratio increase and levels of lactate 
decrease at 72 hours post-dose in TCDD-treated mice relative to controls.  It has been 
reported that, in primary Sertoli cell cultures, TNF-α stimulates lactate dehydrogenase 
(isoform A) expression and activity through the SphM hydrolysis pathway (more 
specifically, via sphingosine production) (Grataroli et al., 2000). 
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FIG. 25. Sphingomyelin Pathway in TCDD-Treated Mice and Rats. Metabolites circled were 
measured by NMR spectroscopy. A rectangle box placed adjacent to a metabolite indicates a 
statistically significant difference in the level of this metabolite (treated vs. control; p≤0.05). 
Information in this box designates: (1) the species that showed change (M=mouse; R=rat), (2) 
whether the metabolite increased or decreased (up or down arrow), (3) the magnitude of change 
(% relative to control), and (4) the designated time-point (h=hour). Bold arrows indicate 
pathways that are activated, dashed arrows indicate pathways that are inhibited. Abbreviations: 
CDP-Eth, CDP ethanolamine, CK, choline kinase; CPT, choline phosphotransferase; DAG, 
diacylglycerol; EK, ethanolamine kinase; EPT, ethanolamine phosphotransferase; Eth, 
ethanolamine; Ser-Eth base exchange, serine-ethanolamine base exchange; GPC, 
glycerophosphocholine; GPE, glycerophosphoethanolamine; PA, phosphatidic acid; Pcho, 
phosphocholine; PchoCT, phosphocholine-CDP cytidyltransferase; PEMT, 
phosphatidylethanolamine methyltransferase; Peth, phosphoethanolamine; Peth-CT, 
phosphoethanolamine-CDP cytidyltransferase; PLC, phospholipase-C; PLD, phospholipase-D; 
PLA1, phospholipase-A1, PLA2, phospholipase-A2; PtdC, phosphatidylcholine; PtdE, 
phosphatidylethanolamine; PtdS, phosphatidylserine; PtdS DC, PtdS decarboxylase; SphK, 
sphingosine kinase; SphM, sphingomyelin; SphMase, sphingomyelinase; TNF-α, tumor necrosis 
factor-α.
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Pcho can also be utilized in de novo PtdC synthesis (Figure 25).  Pcho is first 
converted to CDP-choline (via Pcho-CDP cytidyltransferase) and then to PtdC (via CDP-
choline:1,2-DAG cholinephosphotransferase).  The NMR spectroscopy analyses show 
that TCDD did not affect PtdC levels in either mice or rats (Figure 9).  The following step 
in the SphM pathway may account for PtdC levels not being affected by TCDD.  The 
next step in SphM turnover is the hydrolysis of ceramide to sphingosine, and sphingosine 
is a potent inhibitor of Pcho-CDP cytidyltransferase (Merrill 1989; Sohal and Cornell, 
1990).  This cytidyltransferase is the rate-limiting enzyme in de novo PtdC synthesis 
from Pcho.  Thus, the regulation of de novo synthesis of PtdC is affected by TCDD in 
rats, to the level of CDP-choline.  The activation of sphingomyelinase and inhibition of 
Pcho-CDP cytidyltransferase are consistent with the large increase in Pcho. 
SphM metabolism continues with the phosphorylation of sphingosine to 
sphingosine-1-phosphate, by sphingosine kinase (Figure 25).  Sphingosine-1-phosphate 
can be dephosphorylated or cleaved to 1) Peth and trans-2-hexadecenal from sphingosine 
or 2) palmitaldehyde from sphinganine.  The aldehyde intermediate can be oxidized to 
FAs.  
Another source of PtdC is from PtdE, via PtdE-N-methyltransferase (Figure 25). 
However, mean PtdE levels did not significantly change in rats (Figure 9).  PtdE 
synthesis is then upregulated via the Kennedy pathway (via Peth-CDP 
cytidyltransferase), and from PtdS via 1) serine-ethanolamine base exchange or 2) PtdS 
decarboxylase.  Thus, Peth and PtdS are both precursors to PtdE (Figure 25).  Mean 
hepatic levels of PtdS decrease by 43% with TCDD treatment in rats at 168 hours post-
dose (Figure 8).  Peth is also decreased due to utilization in the Kennedy pathway.  Also, 
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the PtdS/PtdE ratio decreased 36% at 168 hours in rats (Figure 11), suggesting that PtdE 
is synthesized from PtdS.  However, it is not known whether this synthesis is via base-
exchange or decarboxylation.  Levels of serine and ethanolamine will be measured from 
the 1H NMR spectra in the near future to determine if TCDD affects the serine-
ethanolamine base-exchange reaction.  It would also be interesting to compare Peth and 
PtdE levels to determine if PtdE is being synthesized from Peth instead of PtdS. 
Interestingly, the PtdC/PtdE ratio changed to a similar extent in both rats (12-22% 
increase at all times) and mice (17-23% increase at 72 and 120 hours) (Figure 10).  This 
suggests that this phospholipid pathway is also affected in TCDD-treated mice.  This is 
corroborated by Pcho and SphM findings.  Although mean hepatic levels of these 
metabolites do not show significant treatment effects (Figures 12 and 18), there is a 
transient effect, whereby a decrease in SphM is accompanied by an increase in Pcho at 
the same time points. 
Metabolites affected in the general phospholipid pathway in TCDD-treated mice 
include GPC and PtdE.  GPC levels are 26% lower in treated mice relative to control 
mice (Figure 19).  PtdE levels decrease 27% at 168 hours (Figure 9).  PtdC can be 
converted to GPC and PtdE to GPE by phospholipases (Figure 25).  
The first step in de novo synthesis of SphM is the condensation of palmitoyl-CoA 
and serine.  Serine loses its carboxyl group via serine palmitoyltransferase to produce 3-
ketosphinganine.  3-ketosphinganine is reduced to form sphinganine.  Sphinganine is 
acylated to dihydroceramides by ceramide synthase, and SphM is produced from 
ceramide.  SphM can also be synthesized by the PtdC-mediated transfer of Pcho to 
ceramide, at the same time releasing DAG, which is a precursor to TAG.  PtdC might be 
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degraded for the synthesis of SphM, which releases DAG to form TAG.  This is 
consistent with TAG results observed in mice (Figure 5).  Choline levels could be 
examined to corroborate this hypothesis.  PtdC synthesizes choline, and choline kinase 
converts choline to Pcho (Figure 25). 
Several groups reported that TCDD enhances the inflammatory response (Clark et  
al., 1991; Katz et al., 1984; Sutter et al., 1991).  This is consistent with liver 
histopathology: inflammatory cells were manifested in TCDD-treated mice (Boverhof et  
al., 2005).  Also, Fan and his group used liver sections from TCDD-treated rats, and 
found that TCDD is capable of increasing the level of TNF-α.  They observed that at 30 
µg/kg TCDD, mRNA levels of TNF-α are greatly increased (Fan et al., 1997).  Also, the 
AhR has a role in the inflammatory response to TCDD.  Thurmond and his coworkers 
reported that, in TCDD-treated animals lacking the AhR in hematopoietic cells, there is 
almost no inflammatory response (Thurmond et al., 1999). 
Sphingomyelin Pathway – Comparison to Genomic Effects
Studies by our group and others found upregulation in gene expression for TNF-α 
and the receptor with TCDD treatment (Fletcher et al., 2005; Kerkvliet 1995; Lee et al., 
2004, Thurmond et al., 1999).  This supports our TNF-α hypothesis.  Also, the mRNA 
expression for sphingosine kinase is upregulated 1.7-fold in rats, supporting TNF-α-
induced activation of sphingomyelinase.  However, this induction occurs at 4 hours, a 
time-point not examined in our study (Boverhof et al., 2006).  We are currently looking 
into measures of TNF-α and mRNA expression from 72 to 168 hours in rats.  In rats, the 
activity of PtdE-N-methyltransferase is downregulated 0.4-fold at 168 hours (Boverhof et  
al., 2006).  While this is not consistent with our NMR spectroscopy findings into PtdC 
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and PtdE levels, a feedback inhibition mechanism may be occurring.  In such a 
mechanism, the activity of PtdE-N-methyltransferase might be upregulated and gene 
expression downregulated.
D.  TCDD Induces Oxidative Stress in both Rats and Mice
This study shows that mean hepatic levels of cardiolipin decreased by ca. 20% in 
both rats and mice at 168 hours (Figure 8).  Cardiolipin is almost exclusively localized in 
the inner mitochondrial membrane.  Cardiolipin and its oxidation products are important 
signaling molecules in apoptosis (Kagan et al., 2004, 2006, 2008).  Cardiolipin oxidation 
is required for release of pro-apoptotic factors from mitochondria into cytosol.  Early in 
apoptosis, massive amounts of cardiolipin translocate the outer mitochondrial membrane, 
and are available to interact with cytochrome c.  Cytochrome c is a cardiolipin-specific 
peroxidase that controls energy metabolism in the electron transport chain shuttle. 
Cytochrome c/cardiolipin complexes are formed, which then generate cardiolipin 
hydroperoxides, or reactive oxygen species (ROS).  ROS production leads to oxidative 
stress, lipid peroxidation (Stohs 1990), and DNA damage (Shertzer et al., 1998; Wahba 
et al., 1988).  It is hypothesized that cardiolipin levels decreasing to a similar extent at the 
same time-point in mice and rats may be indicative of mitochondrial damage or ROS 
production.  
One study reported that mitochondria play a role in TCDD-elicited oxidative 
stress (Senft et al., 2002a), based on decreases in ATP, cytochrome oxidase, and 
aconitase activity.  The decreased aconitase activity results in increased levels of 
superoxide, and thus ROS.  Glutathione peroxidase, glutathione reductase, and thiol 
levels are increased.  Mitochondrial damage and oxidative stress in rodents treated with 
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TCDD have been reported.  In TCDD-treated rats, signs of oxidative changes include 
increased lipid peroxidation and decreased membrane fluidity (Stohs et al., 1989).  In 
livers of C57BL/6 mice, oxidative stress is characterized by increases in oxidized to 
reduced glutathione (GSSG/GSH) (Shertzer et al., 1998).  The decreased membrane 
fluidity is consistent with increased cholesterol uptake in TCDD-treated mice.  The 
structure of cholesterol plays a role in maintaining the fluidity of cell membranes. 
Cholesterol has a rigid ring system and a short branched hydrocarbon tail, which 
interferes with close packing of FA tails.  The high levels of cholesterol in TCDD-treated 
mice may be the cause of the decreased membrane fluidity.  Thus, the literature has 
shown TCDD causes oxidative stress in mice and rats, and is supported by our 
cholesterol data. 
Oxidative Stress – Comparison to Genomic Effects
Reports have shown that TCDD induces genes associated with the response to 
chemical stress and xenobiotic metabolism.  Members of the AhR gene battery are 
induced by TCDD.  The AhR gene battery includes Cyp1a1, NAD(P)H dehydrogenase, 
and xanthine dehydrogenase.  TCDD also induces increases in glutathione transferases. 
The induction of glutathione transferases catalyzes the conjugation of reduced glutathione 
to products of oxidative stress (Raza et al., 2002).  ROS formation by TCDD depletes 
GSH levels, leaving cells susceptible to oxidative damage.  Such GSH-synthesizing 
enzymes are glutamate-cysteine ligase (1st and rate-limiting step) and glutathione 
synthase (2nd step), both of which are induced by TCDD.  Another gene induced by 
TCDD is UDP-glucose dehydrogenase.   This dehydrogenase catalyzes the step going 
from UDP-glucose to UDP glucuronic acid, which is then conjugated to reactive 
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xenobiotics.  Their induction serves an important role in detoxification, but may also 
contribute to ROS formation, leading to cellular oxidative stress and DNA fragmentation 
(Barouki and Morel, 2001; Boverhof et al., 2005).  
The AhR plays a role in ROS production.  Senft and coworkers found that TCDD-
induced ROS was dependent on the AhR in female mice, but independent of CYP1A1 
and CYP1A2 (Senft et al., 2002b).  Using AhR, CYP1A1, and CYP1A2(-/-) knockout 
mice, only AhR(-/-) mice were protected from TCDD-induced production of 
mitochondrial ROS and an oxidative stress response. 
Future work will continue to probe into this oxidative damage hypothesis.  Levels 
of choline and betaine will be measured from 1H NMR spectra of aqueous extracts. 
Choline is a precursor to betaine, a hepatic osmolyte that protects against the 
development of steatosis (Patrick 2002).  It is also involved in ischemia/reperfusion 
injury, possibly by the inhibition of Kupfer cell activation (Wettstein et al., 1997). 
Betaine may be involved in steatosis and mitochondrial damage.  Also, glutathione levels 
will be examined.  It was not possible to identify, for certain, which peaks were the 
cysteine, glycine, and glutamate moieties of glutathione due to the overlap of multiple 
peaks in the spectrum.  Total Correlation Spectroscopy (TOCSY) will be performed in 
the near future to resolve this problem. 
V.  CONCLUSIONS
Female i.o. C57BL/6 mice treated with TCDD exhibit steatosis, but not Sprague-
Dawley rats, based on liver lipid content, PCA, and metabolic data from NMR 
spectroscopy.  Liver lipid content significantly increased in TCDD-treated mice but not 
rats.  PCA of lipids using 13C NMR spectroscopy showed separation between control and 
treated mice but not rats.  Consistent with these findings, mice show increases in TAG, 
cholesterol, and n3 and n6 FAs.  Lipid accumulation in mice can be due to increased 
hepatic TAG synthesis, FA mobilization from adipose tissue to liver, and increased 
cholesterol uptake.  In mice, liver aqueous extracts revealed decreases in the 
lactate/pyruvate ratio and DHAP levels.  These findings are consistent with the decreased 
cytosolic NADH/NAD+ ratio and upregulated TAG synthesis.  TCDD-treated rats 
exhibited ca. 34% lower levels of hepatic SphM, and three-folds higher Pcho levels, 
suggestive of sphingomyelinase activation by TCDD, perhaps by TNF-α.  Decreased 
cardiolipin at 168 hours in both rats and mice may indicate that TCDD causes 
mitochondrial damage, or ROS production.  These observations are consistent with 
hepatic histopathology and clinical chemistry, and support the hypothesis that TCDD 
elicits species-specific AhR-mediated effects.  Further work into gene expression at the 
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APPENDIX A – Abbreviations
1,3BPG ––– 1, 3-bisphosphoglycerate
ACC ––– acetyl-CoA carboxylase
AhR ––– aryl hydrocarbon receptor
αKG ––– α−ketoglutarate
ANOVA ––– analysis of variance
Asp ––– aspartate
AST ––– aspartate aminotransferase
bHLH-PAS ––– basic helix-loop-helix period-aryl hydrocarbon nuclear translocator-single-minded domain
CDCl3 ––– deuterchloroform
CDP-Eth ––– CDP ethanolamine
CHCl3 ––– chloroform
CK ––– choline kinase
CoA ––– coenzyme A
CPT ––– choline phosphotransferase
Cs2EDTA ––– cesium ethylenediaminetetraacetic acid
CsOH ––– cesium hydroxide
CYP1A1 ––– cytochrome P-450 family 1a1
D2O ––– deuterium oxide
DAG ––– diacylglycerol
DAG acyltransferase ––– diacylglycerol acyltransferase
DAG kinase ––– diacylglycerol kinase
DH ––– dehydrogenase
DHAP ––– dihydroxyacetone phosphate
EDTA ––– ethylenediaminetetraacetic acid
EK ––– ethanolamine kinase





FA ––– fatty acid
FA acyl-CoA ––– fatty acid acyl-coenzyme A
Fasn ––– fatty acid synthase
FID ––– free induction decay
FR ––– fully relaxed
G3P ––– glycerol-3-phosphate
G3P-DH ––– glycerol-3-phosphate dehydrogenase
G6P ––– glucose-6-phosphate
G6Pase ––– G6P phosphatase





GSH ––– reduced glutathione
GSSG/GSH ––– oxidized to reduced glutathione 
HSD –––honestly significant differences
HMG-CoA –––hydroxymethylglutaryl-coenzyme A
i.o. ––– immature ovariectomized
LD50 ––– lethal dose
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LDH ––– lactate dehydrogenase
LPC ––– lysophosphatidylcholine
LSM ––– least squares means
Lyso-PA ––– lyso-phosphatidic acid
MDH ––– malate dehydrogenase
MDPA ––– methylenediphosphonic acid
MeOH ––– methanol
n ––– number of samples
Na2EDTA ––– sodium ethylenediaminetetraacetic acid
NA ––– not appropriate
NADH ––– reduced nicotinamide adenine dinucleotide
NAD+ ––– nicotinamide adenine dinucleotide
NMR ––– nuclear magnetic resonance
NOE ––– nuclear overhauser effect
NS ––– not significant, no significant difference detected
OAA ––– oxaloacetate
OPLS-DA ––– orthogonal partial least squares discriminant analysis
PA ––– phosphatidic acid
PA phosphohydrolase ––– phosphatidic acid phosphohydrolase
PCA ––– principal component analysis
PC ––– pyruvate carboxylase
Pcho ––– phosphocholine
Pcho-CT ––– phosphocholine-CDP cytidyltransferase
PDH ––– pyruvate dehydrogenase
PEMT ––– phosphatidylethanolamine methyltransferase
PEP ––– phosphoenolpyruvate
PEPCK ––– phosphoenolpyruvate carboxykinase
Peth ––– phosphoethanolamine
Peth-CT ––– phosphoethanolamine-CDP cytidyltransferase
PFK ––– phosphofructokinase 
PK ––– pyruvate kinase
PLC ––– phospholipase-C
PLD ––– phospholipase-D
PLA1,A2 ––– phospholipase-A1 and A2
PND ––– post-natal day





PtdS-DC ––– phosphatidylserine decarboxylase 
Pyr ––– pyruvate
ROS ––– reactive oxygen species
SE ––– standard error of the mean
Ser-Eth base exchange ––– serine-ethanolamine base exchange
SF ––– saturation factor




TCA ––– tricarboxylic acid cycle, Krebs cycle
TCDD ––– 2,3,7,8-tetrachlorodibenzo-p-dioxin
TNF-α ––– tumor necrosis factor-α
TSP ––– trimethylsilyl-3-propionic acid sodium salt
TOCSY ––– total correlation spectroscopy
TPI ––– triose phosphate isomerase
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APPENDIX B – Experimental Protocol
  
Sprague Dawley Rats (n=30)C57BL/6 Mice (n=30)
0.1 mL sesame oil (n=15 each) 10 µg/kg TCDD (n=15)









FAs, TAG, cholesterol small 
metabolites
13C NMR 31P NMR 1H NMR 31P NMR
Michigan State University
Wright State University
30 µg/kg TCDD (n=15)
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APPENDIX C – QUANTIFICATION
Using cholesterol data
Data Entry:
Volume CDCl3 for sample reconstitution (mL) 0.600
Volume sample transferred to NMR tube (mL) 0.500
Volume Cs2EDTA soln in NMR tube (mL) 0.200
Change in vol factor for aqs/organic sample 0.355
Final volume in NMR tube (mL) of CDCl3 phase 
= Volume of sample transferred to tube + 0.355*Volume of Cs2EDTA
= 0.5 + 0.355*0.2
= 0.571
Density CDCl3 = 1.500 g/mL
MW of CDCl3 = 120.4
[CDCl3] in NMR tube (mM) 




Tissue weight (g) = 0.499
Intensity of CDCl3 = 100
Saturation Factor:
Under fully relaxed and partially saturated conditions, intensity of CDCl3 = 100
Intensity for cholesterol under:
Fully relaxed (FR) conditions 0.0861734
Partially saturated (PS) conditions 3.18622
# equivalent carbons and corrected intensity for cholesterol (CH3) = 1
Divided the FR and the PS value by 1 = 0.0861734 and 3.18622, respectively
Integral ratio (chol/CDCl3) FR/CDCl3 = FR/100 = 0.00086
PS/CDCl3 = PS/100 = 0.032
SF = FR/PS = 0.027
Let PtdC = Metabolite X
Intensity of Metabolite X = 13.084
# equivalent Cs and corrected integral for X = PtdC/1 
= 13.084
Intensity ratio measured (X/CDCl3) = intensity of PtdC/intensity of CDCl3 
= 13.084/100 
= 0.13084
Intensity ratio corrected for saturation (X/CDCl3) = SF*0.13084 
= 0.027*0.13084
= 0.0035387
[Metabolite X] in NMR tube (mM) = 0.0035387*[CDCl3] in NMR tube 
                                                         = 38.6
[Metabolite X] in reconstituted sample (mM) 
= 38.6*(final volume in NMR tube of CDCl3 phase/volume sample transferred to tube) 
= 38.6 * (0.571/0.500) = 44.09
Metabolite X (µmol) = 44.09*volume CDCl3 for sample reconstitution 
= 44.09*0.600 
= 26.45




Let cholesterol = Metabolite X
Intensity of Metab X = 1.23671
# equivalent Cs and corrected integral for X = intensity for cholesterol/1 
= 1.23671/1
= 1.23671
Intensity Ratio Measured (X/CDCl3) = 1.23671/intensity of CDCl3 
= 1.23671/100
= 0.0123671
Intensity Ratio – Corrected for saturation (X/CDCl3) = (0.0123671*SF) 
= 0.0123671*0.027
= 0.000334476
[Metab. X] in NMR tube (mM) = 0.000334476*[CDCl3] in NMR tube
= 0.000334476*10909.345
= 3.64891721
[Metab X] in reconstituted sample (mM) 




Metab. X (µmol) = 4.167063454*volume CDCl3 for sample reconstitution
= 4.167063454*0.600
= 2.500238073
µmol/g tissue = 2.500238073/tissue weight
                     = 2.500238073/0.499
= 5.01049714
86








p ≤ 0.05p > 0.05
p > 0.05
p > 0.05 p ≤ 0.05
p ≤ 0.05
